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CHAPTER I 
 
INTRODUCTION 
 
Portions of this Introduction have been published in a review article in Trends in 
Endocrinology & Metabolism, by Hubler, Peterson, and Hasty2. 
 
Obesity epidemic and type 2 diabetes 
 The obesity epidemic: Obesity is defined as a body mass index greater than 30. 
This weight-to-height ratio is an indicator of excess adipose tissue. Adipose tissue 
hypertrophy is an important functional adaptation for survival through times of low food 
availability in most mammals. However, just like many physiologic systems, lipid storage 
in adipose tissue has a maximum healthy capacity. With changes in cultural eating 
habits, reduced physical demands, and the ready availability of palatable foods, humans 
are exceeding their natural adaptation to store fat. In the United States, the prevalence 
of obesity is 30% in adults and 17% in children3. In 2008, the CDC attributed an extra 
annual medical cost of $1,429 to obesity in patients3. This disparity can be explained in 
large part by obesity-associated metabolic conditions – including the triad of the 
metabolic syndrome: hypertension, hyperglycemia, and hyperlipidemia. Unfortunately, 
obesity is a risk factor for cardiovascular disease, type 2 diabetes, and even cancers 
and asthma.  
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 Diabetes: Diabetes occurs when the body is unable to sufficiently regulate serum 
glucose levels, leading to hyperglycemia. High levels of serum glucose cause to 
vascular endothelial damage from to excess intracellular glucose and aberrant protein 
glycation4. The resulting vascular and neurological damage can lead to organ 
dysfunction in the eye, kidneys, pancreas, and heart. Serum glucose is regulated by 
insulin, a hormone secreted by beta cells of the pancreas. Insulin induces glucose 
uptake into tissues and reduces glucose production. Diabetes has been classified into 
two types, with deficits in insulin common to both. Type 1 diabetes presents early in life 
and is associated with auto-immune destruction of insulin-secreting beta cells5. The 
etiology of type 1 diabetes is thought to be an autoimmune response to an 
environmental stimulus in genetically predisposed individuals. In contrast, type 2 
diabetes is closely associated with obesity. Disordered energy utilization and storage, 
and subsequent inflammatory responses, lead to progressive tissue insulin resistance 
(IR)6. Eventually insulin demand exceeds the functional capacity of the pancreas, 
causing beta cell death and insulin deficiency.  
 Insulin resistance, pre-diabetes, and type 2 diabetes lay on a continuum of 
disorder that reflects the tissues resistance to insulin signals, and the ability of beta cells 
to compensate. Over time, beta cells are unable to contend with insulin demand, 
leading to beta cell failure. In the liver, normal insulin signaling allows for glucose uptake 
and maintains gluconeogenesis and glycolysis appropriately. In AT and muscle, insulin 
signaling is primarily responsible for glucose disposal7. Insulin acts on these tissues by 
binding the insulin receptor, thereby activating insulin receptor substrate 1 (IRS1). 
Through a cascade of signaling molecules, protein kinase B (Akt2) is activated. This can 
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directly lead to translocation of the glucose receptor 4 (GLUT-4) to the cell surface, and 
can stimulate glycogen synthase. In the liver and AT, insulin signaling also activates de 
novo lipogenesis through sterol regulatory element-binding protein c (SREBP1c). The 
pathogenesis of insulin resistance in AT is complex, involving ectopic lipid deposition, 
adipokines/cytokines, and inflammatory stimuli, all acting on the insulin signaling 
cascade. For example, lipids like diacylglycerol can act through PKCs to inhibit IRS1, 
and inflammatory cytokines like tumor necrosis factor α (TNFα) can act through c-Jun 
N-terminal kinase 1 (JNK1) to inhibit IRS17. Adipokines, cytokines, and inflammatory 
signals involved in AT insulin resistance are outlined in the next sections. 
 
AT endocrine function and inflammation  
AT secretes cytokines, chemokines, adipokines, and other proteins that act locally and 
systemically to control lipid, glucose, and energy homeostasis8. Furthermore, in obesity, 
a pro-inflammatory milieu of immune cells within the AT alters its ability to maintain 
these homeostatic controls. Interestingly, almost all cells of the innate and adaptive 
immune system have been found in both lean and obese AT, with their proportions 
changing to promote inflammation and IR in obesity9. Recognizing the endocrine 
function and inflammatory responses of AT is a major step in understanding why AT 
malfunction is associated with systemic changes in metabolic health. 
 Chemokines, cytokines and adipokines: Unhealthy expansion of AT is 
associated with increased levels of the inflammatory cytokine, tumor necrosis factor α 
(TNFα). The discovery of TNFα expression in obese AT was foundational to the field of 
immunometabolism nearly two decades ago10, because adipose-tissue macrophages 
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(ATMs) have been shown to be the primary source of TNFα in obese AT10. Interleukin-6 
(IL-6) is also highly expressed in AT and correlates with obesity, but its exact role in 
obesity is contended; while IL-6 deficient mice show metabolic dysfunction, 
administration of intravenous IL-6 also leads to insulin resistance11. Adipocytes treated 
with TNFα produce 34 different chemokines associated with monocyte recruitment12. 
Therefore, elevated TNFα when ATMs infiltrate can feed-forward to amplify further 
recruitment.  
 Adipokines are hormones produced by AT to communicate with other organs and 
systems in the body. The discovery of these molecules changed the appreciation of AT 
from an inert lipid depot, to an actively signaling organ. Two major adipokines – leptin 
and adiponectin – play a role in feeding and energy expenditure through the central 
nervous system13, and directly impact AT inflammation. Leptin deficiency is associated 
with hyperphagia. However, obese humans and mice have higher levels of serum leptin, 
indicating a state of central leptin resistance, possibly mediated through inflammatory 
signals14. Leptin also activates ATMs to produce pro-inflammatory cytokines15. In 
contrast, adiponectin is considered an anti-inflammatory adipokine, and its expression is 
suppressed by inflammatory cytokines, as well as oxidative stress16, and iron overload 
(discussed below)17. Adiponectin acts through AMPK to increase glucose uptake and 
fatty acid oxidation, and to reduce liver gluconeogenesis18. Studies in mice with 
adiponectin excess or deficiency support its role in insulin sensitization19, 20.  
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 Inflammatory cells in AT: Macrophages are the most common immune cell in 
AT. ATMs are localized in interstitial spaces suggesting communication between the 
two cell types, and a role for macrophages in AT homeostasis. Over the last decade21, 
ATMs have been proposed to be involved in AT development, expansion22, 23, antigen 
presentation24, and catecholamine synthesis25. In obesity, there is a large influx of 
macrophages from the monocyte pool, such that up to 40% of cells in obese AT are 
macrophages26. These ATMs accumulate in crown-like structures around dead 
adipocytes27, 28 and have a gene expression profile reflective of a more classically 
activated, M1-like phenotype29. Inflammatory ATMs are thought to contribute to IR in AT 
by secretion of inflammatory cytokines, such as TNFα and IL-1β. However, recent 
studies have demonstrated that even though inflammatory ATMs from obese AT 
express many inflammatory cytokines, they have a phenotype that is distinct from 
infection-associated inflammatory macrophages; Kratz et al. used proteomics and 
functional studies to identify the “metabolically activated” (Mme) phenotype30. Mme 
ATMs exist in obese AT and have a balance of pro-inflammatory and anti-inflammatory 
signaling pathways that keep them in a state of unresolving inflammation. They are 
activated by glucose, insulin, and palmitate, through toll-like receptor 4 (TLR4), and 
have unique cell surface expression of CD36, PLIN2, and ABCA1. They have low 
expression of classic M1 markers, but also M2 markers, e.g. cluster of differentiation 
(CD) 163 and CD206. This finding further emphasizes that macrophages may take on 
tissue-specific phenotypes in response to their local environment. Furthermore, Mme 
polarization of in vitro macrophages, using glucose, palmitate and insulin, can now be 
implemented as a more representative model of inflammatory ATMs. 
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 DCs in AT are predominantly conventional CD11b+ DCs, and their numbers 
increase in obesity31. AT DCs can be distinguished from ATMs because they are 
negative for CD64 but commonly express CD11c. Like ATMs, they can stimulate the 
proliferation of CD4+ T cells. 
  Neutrophils are commonly first-responders in the innate immune system. 
Studies have shown that a neutrophil influx occurs early in obesity, indicating that 
neutrophils may be involved in initial recruitment of immune cells. However, neutrophils 
are not common in lean AT, and neutrophil accumulation in AT in obesity is 30-fold 
lower than macrophages32.  
 Eosinophils were first described in AT by Wu et al33. They were found to be more 
abundant in lean AT than obese AT, and their presence correlated with M2-like 
polarization of ATMs. Using both a eosinophil-deficient model (dblGATA) and 
eosinophilia model (IL-5 transgenic) the authors concluded that eosinophils protected 
AT from metabolic dysfunction33. However, our lab recently published a model using 
chronic IL-5 injections to induce AT eosinophilia in diet-induced obesity34. These studies 
showed that eosinophils are not sufficient to protect AT from metabolic dysfunction in 
obesity34.  
 Mast cells are generically associated with allergic responses, but their counts are 
also increased in obese AT35. In fact, genetic mast cell knockout studies have shown 
that their deficiency reduces weight gain, and possibly ATM accumulation35. Basophils 
are similar to mast cells, but no specific role for this cell type has been delineated in AT, 
and their lineage marker is not highly expressed36.  
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 Both Th1 and Th2 T lymphocytes cells are present in AT. Total T-cell knockout 
mice have worsened metabolic profiles and weight gain. This may be because some 
CD4+ T cells, such as regulatory T cells, have also been shown to be protective against 
metabolic function37, 38. In contrast, studies have shown that CD3+ Th1 T cells increase 
with obesity, and their expression of the cytokine INFγ may exacerbate insulin 
resistance in the tissue39. When CD3-neutralizing antibodies were administered to mice, 
a phenotypic switch was observed in ATMs from M1 to M240.   
 
Association of obesity and metabolic syndrome with iron  
 The role of chemokines, cytokines and inflammatory cells in metabolic 
dysfunction in AT has been revealed over the course of the last decade. However, it is 
only now coming to light that iron overload of adipocytes also contributes to local and 
systemic IR17. The association between obesity, inflammation, and adipocyte iron 
overload is an area of new interest outlined in the sections below, and fundamentally 
underlies the goals of research efforts outlined in Chapters III-V.  
 In humans, elevated body iron stores have repeatedly been linked to factors 
comprising the metabolic syndrome, including obesity, dyslipidemia, hypertension, 
fasting hyperglycemia, and diabetes41-48. An analysis of four different studies on the link 
between iron and diabetes demonstrated that men and women in the highest quintile of 
serum ferritin (Ft) levels – the primary intracellular iron-storage protein that can be 
released in overload situations – had a relative risk of greater than 3.5 for developing 
diabetes49. In fact, this condition is now called dysmetabolic iron overload syndrome 
(DIOS)50 and it has even been suggested that serum Ft may serve as a surrogate 
	   8	  
marker for insulin resistance51. Although inflammatory cytokines can influence iron 
storage in various cell types, studies have shown that the link between elevated iron 
and obesity/diabetes is independent of inflammation41, 43. It is also not associated with 
dietary iron intake or absorption52 or to beta cell function53. Further supporting the 
relationship between iron and metabolic disease, a recent 7-year prospective study 
found that serum Ft was positively associated with the clinical indicator of IR, HOMA2-
IR, and both hepatic and adipocyte IR54. This aligns well with the finding that IR is 
associated with changes in iron-handling proteins in AT55. Furthermore, iron depletion 
by phlebotomy, even in healthy subjects, has been shown to improve insulin 
sensitivity56. Although extensive research efforts have been focused on understanding 
the association between obesity and the metabolic syndrome, mechanisms for impact of 
iron on metabolic health have not been well elucidated.  
 Despite the link between iron-overload and obesity mentioned above, 
inflammation in obesity also leads to iron-deficient anemia57. Linking obesity with both 
tissue iron overload and iron deficient anemia may seem counterintuitive. However, this 
occurs because macrophages sequester iron during chronic inflammation. The 
mechanism underlying this phenomenon can be understood by parsing out systemic 
and cell autonomous regulation of iron storage, as detailed below.  
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Systemic and cellular iron cycles 
 Systemic iron handling: Iron is absorbed from the diet through apical 
transporters on duodenal enterocytes. It is released basally from enterocytes through 
the only known mammalian iron exporter, ferroportin 1 (Fpn1). In serum, iron is found in 
three main forms: Fe3+ bound to transferrin (Tf), heme bound to hemopexin, or 
hemoglobin bound to haptoglobin. In bone marrow erythroblasts, iron is used to form 
hemoglobin for incorporation into nascent erythrocytes. Senescent erythrocytes are 
phagocytized by splenic macrophages and the iron is recycled back to the erythroblasts. 
The development of these splenic red pulp macrophages is dependent on the 
expression of SpiC (gene SpiC)58. Overall, ten times more iron is recycled by 
macrophages than is even absorbed through the duodenum59. Resident macrophages 
are responsible for iron-cycling in many tissues, including bone marrow, spleen60, 
liver61, and lung62. Macrophages also express receptors for all three types of iron that 
are present in serum; transferrin receptor (TfR1) binds Fe3+-Tf, CD91 binds heme-
hemopexin, and CD163 binds haptoglobin-hemoglobin (Hp-Hb).  
 Regulation of systemic iron: The systemic uptake and release of iron is 
regulated through the acute phase reactant protein hepcidin, which is secreted by 
hepatocytes. Hepcidin induces Fpn1 endocytosis and degradation63 and therefore 
regulates the primary control points of plasma iron: absorption of iron from the intestine, 
release of stored iron from hepatocytes, and recycling of iron by macrophages. This is 
also the primary pathway for regulated iron clearance: hepcidin reduces Fpn1 on 
enterocytes, leading to the sequestration of iron in cells that will be sloughed off and 
excreted64. In acute infection, hepcidin-induced iron sequestration results in dramatic 
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reductions in plasma iron as a bacteriostatic mechanism. Hepcidin is also synthesized 
by adipocytes65 and macrophages66. Under homeostatic conditions, hepcidin production 
is induced through signaling of the bone morphogenetic protein 6 (BMP6)/Smad 
pathway with a co-receptor for BMP6, hemojuvelin. During inflammation, this is 
accomplished via the IL-6/STAT3 pathway67.  
 Effects of obesity on systemic iron concentrations: Inflammatory signaling, 
often associated with chronic diseases such as obesity, is associated with increased 
expression of hepcidin, via IL-6 induction, and can lead to anemia of chronic disease – 
a disease in which tissue iron overload and anemia occur concomitantly. Increased 
circulating hepcidin can explain this apparent conundrum. Cells such as macrophages, 
enterocytes, and hepatocytes have high iron uptake and depend on Fpn1 for iron 
release68. Therefore, when hepcidin is up-regulated, Fpn1 is down-regulated and iron is 
sequestered, reducing its availability in plasma. A consequence of decreased plasma 
iron levels is reduced availability for erythrocytosis, thereby leading to anemia. Thus, in 
the case of chronic inflammation-induced hepcidin expression, increased serum Ft is 
reflective of tissue iron overload that occurs concomitantly with anemia.  
 Obesity has also been directly linked to changes in iron storage. For example, in 
the liver, high-fat/high-sucrose diet induces hepatic iron storage69. However, these 
findings are still conflicted, as some studies have shown a decrease in liver iron in 
obese mice70, 71. It is thought that iron accumulation in certain cells not only alters iron-
handling genes but also changes inflammatory cytokine expression. These conflicting 
studies demonstrate that there is still much to be learned regarding the reciprocal 
regulation of iron and inflammation in obesity. 
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 Regulation of  the cellular iron cycle: Cellular iron regulation is important 
because excess free iron in a cell can readily cause oxidative damage. Following 
endocytosis via one of the iron receptors, iron is released from is carrier proteins by 
acidification of the endosome, and transported across the endosomal membrane by 
divalent metal transporter 1 (DMT-1) to be bound by Ft, or incorporated into iron-
containing proteins. The proteins involved in cellular iron handling are translationally 
controlled in response to intracellular iron concentrations72. This occurs through iron-
response proteins (IRPs) that can bind iron-response elements (IREs) to either stabilize 
or de-stabilize mRNAs for iron-related transcripts. In iron-deplete cells, IRP1 and IRP2 
bind IREs in the 3’ untranslated region (UTR) of Tfrc (gene for TfR1) and Slc11a2 (gene 
for DMT-1) and in the 5’ region of Fth1 and Ftl1 (FtH, FtL, respectively) and Slc40a1 
(gene for Fpn1). Binding in the 3’ UTR stabilizes the mRNA for TfR1 and Slc11a2, 
whereas binding in the 5’ UTR inhibits translation of Fth1 and Slc40a1. Ultimately, 
protein levels of TfR1 and DMT-1 are elevated, while levels of Ft and Fpn1 are reduced. 
The overall effect is that more iron is imported into the cell, less is bound by Ft, and less 
is exported. Effectively, active IRPs increase the cell’s labile iron pool (LIP) - the 
transitory, chelatable, and redox-active iron pool in a cell. When the cell becomes iron-
replete, IRP1 is bound by an iron-sulfur cluster to form c-aconitase, and IRP2 is 
ubiquitinated and degraded. Ft levels increase and Ft is released at concentrations 
proportional to its expression in the cells. Due to this fine-tuned regulation, Ft is 
commonly used as a surrogate measure of body iron stores in humans51.  
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Figure 1.1. Schematic of systemic and cellular iron handling. Dietary iron is taken up via DMT-1 on 
enterocytes. It is transferred into the plasma through Fpn1, where it is again oxidized and binds Tf. 
Thereafter, it is primarily transported to bone marrow to produce heme for erythrocyte formation. In the 
spleen, most of the iron taken up by macrophages derives from phagocytosis of senescent red blood cells. 
However, systemic macrophages can also reabsorb iron through three primary receptors: CD163 binds 
hemoglobin-haptoglobin complexes, CD91 binds heme-hemopexin complexes, and TfR1 binds Tf-Fe3+. 
Once bound, the receptor is endocytosed and a change in pH induces the reduction of iron and its release 
into the cytoplasm. In the cytoplasm, iron exists in three forms; bound by Ft, incorporated into proteins, or 
retained as part of the unbound LIP. Iron is released from cells through Fpn1, again to be bound by Tf. 
Hepcidin is secreted from the liver in response to acute and chronic inflammatory stimuli and functions to 
degrade Fpn1, primarily on enterocytes and macrophages. [Cp: ceruloplasmin; DMT-1: divalent metal 
transporter 1; Fpn1: ferroportin 1; Tf: transferrin; TfR1: transferrin receptor 1; Hmox1: Heme oxygenase 1; 
Ft: ferritin]. 	  
	   13	  
Genetic iron overload disorders 
 The relationship between obesity and cellular iron overload contrasts with 
findings in genetic forms of iron overload, such as hereditary hemochromatosis. Genetic 
causes of iron overload are most commonly caused by defects in hepcidin leading to 
inappropriately high Fpn1 on the cell surface73. With constitutively elevated Fpn1, 
enterocytes continually import dietary iron into serum, and excess iron is stored in 
tissues such as the liver, heart, and endocrine organs that have naturally lower Fpn1 
levels, thereby lower iron export. Iron is initially not deposited in macrophages and 
enterocytes because they can upregulate Fpn1 to export the excess iron; however, in 
later stages of this disease, even macrophages can become iron-loaded. These 
disorders are associated with an increased prevalence of diabetes, likely due to iron-
mediated toxicity to the pancreas74. While it is not considered a genetic disorder, it has 
also been shown that genetic variants in iron-related genes, such as HFE, Slc40a1, and 
even beta-globin genes, can impact the pathogenesis of DIOS75, 76. 
 
Adipocytes and iron 
  
 Based on multiple studies correlating obesity and metabolic syndrome to iron 
overload, it is of no surprise that scientific attention has recently turned to iron in AT. In 
vitro and in vivo studies by several different groups have begun to elucidate the role of 
iron in lipid handling, mitochondrial biogenesis, and other adipocyte functions.  
 Iron and adipocyte lipid handling: Iron can impact adipocyte lipid handling in 
several ways, including lipid accumulation in adipogenesis, lipid release in lipolysis, and 
lipid peroxidation. As shown by in vitro 3T3-L1 differentiation models, adipocytes require 
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iron for adipogenesis77. Conversely, knockdown of Tf or Ft light chain (FtL), as well as 
iron chelation, result in iron depletion and antiadipogenic effects in human AT 
explants77. Iron also alters adipocyte lipolysis and lipid peroxidation. For example, iron 
treatment of primary adipocytes is sufficient to reversibly increase lipolysis78 and reduce 
insulin-mediated glucose uptake79. The mechanism underlying this iron-induced lipolysis 
is not through canonical lipolysis regulatory pathways (such as cAMP, MAP kinase, 
protein kinase C, or phosphatidylinositol 3-kinase). Rather, iron-induced lipolysis can be 
inhibited by a free-radical scavenger, and can be mimicked by 4-hydroxy-2-nonenal (4-
HNE), a by-product of lipid peroxidation78, 80. Lipid peroxidation is an end product of 
excess reactive oxygen species (ROS) in adipocytes, and increases with increased iron. 
Therefore, iron likely induces lipolysis through a pro-oxidant mechanism. These studies 
suggest that regulation of adipocyte iron exposure in a temporal and concentration 
dependent manner is a priority for maintaining healthy AT expansion. 
 Iron, mitochondrial function and biogenesis: Mitochondria depend on iron for 
many functions, including regulation of cellular redox potential, regulation of apoptotic 
cell death, and production of iron-sulfur clusters, steroids, and heme81. Adipocyte iron 
depletion decreases expression of the mitochondrial transcription factor, Tfam, 
indicating decreased mitochondrial transcription and replication. Conversely, 
mitochondrial biogenesis is upregulated during adipogenesis. Iron and IRPs have been 
shown to reversibly stimulate mitochondrial biogenesis and activity77, which is also a 
primary mechanism for the efficacy of pharmaceutical agonists of peroxisome 
proliferator-activated receptor gamma commonly used to treat diabetic patients82. 
Therefore, adipocyte iron concentrations must be maintained within a proper range to 
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allow for proper mitochondrial biogenesis and function, without being so high that 
oxidative stress occurs. 
 Iron overload in adipocytes: Several recent studies have explored the impact 
on iron overload on adipocyte function. In a study by Dongionvanni et al., mice fed a 
high-iron diet developed IR in visceral AT50. In contrast, a low-iron diet has been 
associated with improved insulin sensitivity in genetically obese leptin deficient ob/ob 
mice83. Furthermore, in mice, high dietary iron was associated with a decrease in the 
insulin-sensitizing adipokine, adiponectin17, as well as an increase in the insulin-
resistance inducing adipokine, resistin50, despite a decrease in fat mass. In two 
separate studies adipocyte-specific Fpn1 knockout mouse models were used to induce 
adipocyte iron accumulation17, 84. Britton et al. did not observe adipocyte iron 
accumulation in Fpn1 knockout mice84, however, Gabrielsen et al. quantified an 
increase in adipocyte Ft in their model17. Their Fpn1 knockout mice also demonstrated 
decreased systemic glucose tolerance in a mechanism driven by reduced serum 
adiponectin. These findings complement studies in humans showing that serum Ft is 
the strongest predictor of low serum adiponectin17, 54, 85. High serum Ft is also 
associated with adipocyte-specific IR, even after controlling for a host of covariates54.  
 Adipocyte dysfunction with high iron: There is no known single mechanism to 
explain the impact of iron on adipocytes; however, iron may impact adipocytes’ 
mitochondrial function and adiponectin production, as mentioned above. What is known 
about adipocyte function and iron is shown diagrammatically in Figure 1.2. Excess free 
intracellular iron leads to amplified production of ROS. These increased ROS alter 
mitochondrial function in adipocytes, contributing to IR86. In fact, oxidative stress from 
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ROS appeared to impair mitochondrial function in adipocytes through FOXO187, and 
FOXO1 activation inhibited adipocyte differentiation29. Interestingly, altered FOXO1 
activation also seemed to underlie the association between adipocyte iron overload and 
reduced adiponectin expression – but by FOXO1 deacetylation, rather than 
dephosphorylation17. These findings suggest that multiple mechanisms for altering 
adipogenesis and adipocyte function converge on the transcription factor FOXO1, and 
that iron-induced oxidative stress and adiponectin can be added to the list. Despite this 
extensive background outlining the impact of iron on adipocyte function, little is 
understood about how iron availability is regulated in AT.  
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Figure 1.2. Mechanisms by which iron alters adipocyte functions. In normal AT, iron 
concentrations are controlled such that adipogenesis, mitochondrial function, and adipokine secretion 
are properly regulated. When adipocyte iron concentrations are elevated, such as in obesity, dietary 
iron excess, and in iron-related diseases, an increase in ROS can lead to FOXO1 activation which can 
result in decreased adipogenesis, decreased mitochondrial function, and decreased adiponectin 
secretion. In addition, ROS promote lipid peroxidation that can lead to uncontrolled lipolysis. [AT: 
adipose tissue; ROS: reactive oxygen species; FOXO1: Forkhead box protein O1] 
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Iron handling by resident AT macrophages  
 Macrophages are responsible for iron handling in most tissues, especially during 
resolution of inflammatory processes and wound healing. In some cases, iron uptake by 
macrophages appears to promote restoration of tissue homeostasis, but macrophage 
iron overload can also contribute to disease processes, with a few examples described 
below.  
 Hemorrhagic plaques: Alternatively activated (M2-like) macrophages have 
increased iron content and atheroprotective effects during atherosclerotic plaque 
rupture. These M2-like macrophages, termed “Mhem”, and “M(Hb)”88-90 were shown to 
take up iron from the local milieu in hemorrhagic plaques. Concomitantly, Mhem/M(Hb) 
macrophages appeared to upregulate lipid export genes. Functionally, this would 
protect the cells from lipid peroxidation that occurs if cellular iron and lipid 
concentrations are elevated simultaneously.  
 Wound healing: Although M1-like macrophages fight infection acutely, anti-
inflammatory M2-like macrophages contribute to resolution of inflammation during 
wound healing. A recent study in chronic venous leg ulcers added even more 
complexity to this model: iron-overloaded macrophages had an unrestrained M1-like, 
pro-inflammatory phenotype, while still expressing high levels of the M2 markers, 
CD163 and CD20691.  
 Cancer: Alternatively activated macrophages in the tumor microenvironment, or 
tumor-associated macrophages (TAMs) are associated with increased iron release, 
which correlates with tumor cell proliferation. In this system, M2-like TAMs promote 
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angiogenesis, while M1-like cells tend to sequester iron and decrease tumor 
development92. 
 Multiple Sclerosis lesions: M1-like macrophages on the edges of demyelinated 
lesions have increased depositions of iron. Interestingly, these macrophages tend to be 
myelin-deplete, while myelin-laden “foamy” macrophages do not contain iron and 
resemble an M2 phenotype93. Furthermore, the count of M2-like iron-laden 
macrophages is higher in patients with active relapsing multiple sclerosis.  
 These examples demonstrate that the polarization of macrophages, their iron 
content, and their ability to recycle iron, contribute to the overall outcome of disease 
processes and resolution of inflammation. Much remains to be understood about how 
macrophages respond to environmental cues in specific tissues to adapt their iron 
handling status. 
 
Iron handling by MFehi macrophages in AT 
 Macrophages are the most abundant immune cell in AT. In lean AT, these 
macrophages have a gene expression profile most similar to an anti-inflammatory, M2-
like phenotype94. Considering macrophages play a prominent role in iron metabolism in 
other tissues, it is possible M2-like ATMs contribute to the local control of iron 
metabolism in AT. In a 2016 publication by Orr et al, the Hasty lab demonstrated that 
25% of macrophages in lean AT have a 2-fold increase in intracellular iron stores, 
allowing them to be isolated based upon their ferromagnetic properties71. While all 
ATMs present in the lean mice were M2-like, the paramagnetic ATMs were referred to 
as “MFehi” and the remaining ATMs as “MFelo” (Fig. 1.3A). Compared to MFelo cells, 
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MFehi cells had a 2-fold elevation in all iron metabolism-related genes quantified, 
including Cd163, Tfr1, Hmox1, Fth, Ftl, and Slc40a1, which was dubbed as a “iron-
cycling” phenotype (Fig. 1.3B). Furthermore, MFehi ATMs had even greater expression 
of M2-associated genes, and a reduction in M1 genes (Fig 1.3C).  
 The increase in all iron-related genes suggested a role for these macrophages in 
iron-recycling rather than iron-storage. Furthermore, in diet-induced obesity, newly 
recruited macrophages did not take on a role in iron handling, and the MFehi cells 
become more inflammatory and appeared to lose their iron-cycling gene profile71. 
Importantly, this change in MFehi cells with regards to iron handling in obesity occurred 
concomitantly with adipocyte iron overload and reduced adipocyte adiponectin 
expression71. Taken together, these studies suggested that MFehi cells are a unique 
population of macrophages that regulate iron homeostasis in AT.  
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Figure 1.3. [Adapted from Orr et al. 2013 73] Profile of high-iron “MFehi” adipose tissue macrophages. 
(A) Iron quantification of magnetically sorted macrophages. (B) Iron-associated gene expression in MFelo and 
MFehi ATMs. (C) Polarization gene expression in MFelo and MFehi ATMs. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
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Macrophage polarization and iron 
 A long-standing dogma in the field of immunology is the association between M1-
polarized macrophages and increased intracellular iron. This view is grounded in the 
observation that iron is sequestered by M1-polarized macrophages in serum following 
spikes in hepcidin during acute inflammation95. In addition, this view holds that patterns 
of gene expression in macrophages either favor iron storage (increased import and 
storage genes) or iron release (decreased storage and increased export genes). The 
study of MFehi cells discussed above contradicts these dogma, showing that MFehi 
ATMs are highly M2-polarized, have increased iron content, and also have high 
expression of all iron-related genes, i.e. iron uptake, storage, and release71 (Fig. 1.3A). 
This could be a phenomenon unique to MFehi cells in AT; however, other studies 
support the observation that M2-polarized macrophages have an iron-cycling 
phenotype96, 97. When these in vitro studies compare M2-polarized to M1-polarized 
macrophages, TfR1 and Fpn1 proteins were both up-regulated in M2 macrophages, 
while Ft was down-regulated. M2 macrophages also had enhanced binding of IRPs to 
IREs, corresponding to an increased LIP and a more flexible iron-cycling phenotype. 
Characterization of in vitro polarized macrophages to in vivo macrophages, like MFehi, 
leaves many questions concerning the mechanisms by which macrophage polarization 
and iron handling are linked.  
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Obesity and the MFehi phenotype 
 In obese mice, MFehi ATMs had decreased iron content as well as decreased 
expression of iron uptake and release genes71. Cytokines such as TNFα, IL-6, IL-1β, 
and saturated fatty acids (SFAs), are important modulators of inflammation in obese AT. 
This can be correlated to in vitro findings; exposure of primary peritoneal macrophages 
to SFAs to induce inflammation reduces expression of iron metabolism genes71. Figure 
1.4 depicts a schematic to summarize our current understanding of the intersection of 
inflammation and iron content in macrophages in vivo and in vitro. 
 Other inflammatory molecules have not been studied extensively in the context of 
iron handling in ATMs; however, in one recent report, high-iron macrophages in the 
spinal cord were shown to be uniquely susceptible to M1 polarization by TNFα98. Thus, 
the inflammatory milieu of obese AT may explain why MFehi ATMs take on a more M1-
like phenotype. The susceptibility of MFehi ATMs to inflammatory polarization relative to 
the other ATMs has not been explored, but may partially explain increased adipocyte 
dysfunction in iron-overloaded humans. Obesity is associated with an increase in the 
cytokine IL-6. In fact, 30% of serum IL-6 is thought to come from visceral AT, and is 
attributed to macrophages, not adipocytes99. IL-6 directly induces the production of 
hepcidin100. Interestingly, in obesity, hepcidin can be secreted by visceral AT, and like 
IL-6, it is produced mainly from macrophages101. Whether hepcidin can be expressed in 
MFehi cells specifically is not known. The production of hepcidin by ATMs could indicate 
that they are responsible for sensing and responding to changes in local iron 
concentrations, causing reduced iron cycling by macrophages and iron retention in 
adipocytes. Differences in IL-6 expression in obesity could also explain changes in 
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hepcidin and iron content between tissues in obesity. For example, hepcidin did not 
increase in the liver in obesity, possibly explaining why elevated iron content was seen 
more in AT than in the liver in obesity71. 
 IL-4 is a potent T helper type 2 cytokine whose expression is reduced in AT in 
obesity. IL-4 has been shown to induce M2-like macrophage polarization; it also inhibits 
NO-induced IRP activation by reducing binding of IRP1 and IRP2 to RNA102, thereby 
decreasing the LIP. Furthermore, IL-4 enhances production of TfR1 mRNA through a 
non-IRP dependent pathway. Thus, IL-4 may serve as a node of control for both 
macrophage polarization and iron handling.  
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Figure 1.4. Inflammation and iron content of macrophages. (A) ATMs can be magnetically isolated 
based upon natural paramagnetic properties due to increased iron stores. MFehi macrophages have 
elevated iron concentrations compared to MFelo macrophages. In both lean and obese mice, MFehi 
macrophages have increased expression of M2-like anti-inflammatory genes and decreased expression 
of M1-like pro-inflammatory genes, as compared to MFelo macrophages from the same animals. It is 
known that obesity induces a pro-inflammatory phenotype in AT macrophages. In high fat diet-induced 
obesity, MFehi macrophages become more inflammatory compared to MFehi macrophages from lean 
mice, but do not exhibit the extent of M1-like inflammatory properties observed in MFelo macrophages 
from obese animals. (B) In vitro polarized M1 and M2 macrophages have unique properties regarding 
iron handling. M1 macrophages have decreased iron uptake and export, and a smaller LIP while M2 
macrophages have an iron recycling phenotype. [LIP: labile iron pool; Ft: gene for ferritin; Hmox1: gene 
for heme oxygenase 1; IRP: iron response protein].   	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Heme oxygenase 1 and macrophage iron handling 
 Heme oxygenase 1 (Hmox1, gene Hmox1) is an enzyme that metabolizes heme 
into iron, bilirubin and CO. It is part of the cellular defense against oxidative stress and 
has largely been considered protective against cellular dysfunction. For example, 
peritoneal macrophages from Hmox1 knockout mice have increased ROS and the 
inflammatory cytokine MCP-1103. However, the cellular role of Hmox1 may be much 
more context-dependent than previously appreciated. In a recent study, macrophage-
specific Hmox1 knockout mice on a high fat diet had decreased AT inflammation and a 
dramatic improvement in nearly every metabolic parameter compared to controls104. 
These findings not only contradict the dogmatic “anti-inflammatory” categorization of 
Hmox1, but also obfuscate the finding that Hmox1 is one of the genes most highly up-
regulated in MFehi ATMs, which are very polarized to the M2-like phenotype. However, 
iron content of macrophages could be very important in determining the impact of 
Hmox1 on cellular function. For example, splenic macrophages are absent in Hmox1-
deficient mice and humans105. Splenic macrophages have high iron content due to 
persistent heme recycling, and their absence in Hmox1-deficient mice indicates that 
Hmox1 may be required for the viability of macrophages with high heme or iron content. 
Interestingly, Hmox1 expression in MFehi ATMs is reduced in obese mice (Fig. 1.3A & 
1.4). Paralleling this, Hmox1 in human M2-polarized macrophages is decreased by the 
inflammatory cytokine IFNγ and increased by IL-4106. Figure 1.5 depicts a schematic to 
summarize our current understanding of the impact of obesity-associated inflammation 
on macrophage iron handling. 
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Figure 1.5. Proposed mechanisms by which obesity could impact MFehi cells. In lean AT, MFehi ATMs 
are highly M2-polarized and express elevated levels of Hmox1 and thereby could breakdown heme into 
CO, bilirubin, and iron in an anti-inflammatory process. In addition, they are exposed to elevated levels of 
IL-4, which could increase TfR1 and NO. An increase in NO has been shown to increase IRP binding and 
therefore the labile iron pool in other settings. In obesity, the MFehi ATMs become more M1-like, likely due 
to the milieu of SFA and inflammatory cytokines such as TNFα and IL-1β. A decrease in Hmox1 could 
result in increased ROS. In vitro studies with cultured macrophages have shown similar mechanisms to 
occur; however, these have yet to be tested in MFehi ATMs. [AT: adipose tissue; Hmox: heme oxygenase 
1; TfR1: transferrin receptor; NO: nitric oxide; ROS: reactive oxygen species; SFA: saturated fatty acid; 
TNFα: tumor necrosis factor α; IL-1β: interleukin 1β]. 
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Summary and significance 
 The impact of the obesity epidemic and its associated metabolic diseases makes 
it imperative that we better understand the intricate relationships between adipocytes 
and the immune system. While much attention has been paid to the function of ATMs in 
obesity, much less is known about the fundamental homeostatic functions of ATMs in 
AT. The  literature described suggests a strong association between iron storage and 
metabolic regulation. In AT, iron levels must be sufficiently high to facilitate 
adipogenesis, while not so high that they induce IR. In addition, the gene expression 
profile of MFehi ATMs suggested that they are M2 polarized and have an iron recycling 
phenotype. This M2-associated “iron-cycling”  phenotype has been substantiated by in 
vitro studies published by other groups.  
 As depicted in Figure 1.6, Chapter III delves into functional questions presented 
by the discovery of MFehi, i.e. Can MFehi ATMs contribute to local control of AT iron 
concentrations, perhaps acting as “ferrostats”? It is yet to be determined how the 
presence of MFehi may protect adipocyte function. Chapter IV outlines studies to 
address the impact of obesity on this hypothesized ferrostatic function of MFehi. Lastly, 
Chapter V outlines methodological attempts to target MFehi in AT. 
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Figure 1.6. Model representing an overview of experimental questions in Chapters III-V. Previous 
studies by our lab demonstrated that MFehi ATMs have increased intracellular iron content. In obesity, the 
iron content of MFehi ATMs is decreased but adipocyte iron increases. Chapter III will aim to understand if 
MFehi ATMs take up exogenous iron, preventing adipocyte iron uptake. Based on the described changes 
in adipocyte iron content in obesity, Chapter IV will provide excess iron in obesity to explore if can still 
serve as an iron-sink. Chapter V explores methods of interfering with MFehi ATM uptake of iron through 
cellular depletion or gene knockdown. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animal care and usage 
 Animal care and procedures described in this chapter were performed with 
approval from the Institutional Animal Care and Usage Committee at Vanderbilt 
University. Experiments used male C57BL/6J mice from The Jackson Laboratory (Bar 
Harbor, ME).  
 
Animal diets 
 Unless specified otherwise, mice were provided standard rodent chow diet 
(LabDiet 5001) with a kcal composition of 12% fat, 28% protein, and 60% 
carbohydrates. All mice were given free access to water.  
 
 Iron diets: For iron diet studies, mice were fed macronutrient-matched iron diets 
that contained low iron levels (35ppm iron, cat. no. TD-10211; Envigo), average iron 
(500ppm, cat. no. TD-10212; Envigo) or high iron (2000ppm, cat. no. TD-10324; 
Envigo) for 8 weeks starting at 8 weeks of age. These dietary iron levels were selected 
because dietary iron as low as 25ppm supports hematopoiesis in C57BL/6J mice, while 
around approximately 250ppm is commonly found in chow diet107, 108. Body weight and 
dietary intake were tracked and mice were provided water and food ad libitum for the 
course of the studies. 
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 Diet induced obesity: In high fat diet (HFD), studies mice were provided diet ad 
libitum consisting of 60% kcal from fat (Research Diets, D12492) for 16-20 weeks. 
Control groups received low fat diet (LFD) consisting of 10% kcal from fat (Research 
Diets, D12450B). 
 
Tissue digestion for SVF and adipocyte isolation 
 Mice were euthanized by isoflurane overdose and cervical dislocation, then 
perfused with 20 ml PBS through the left ventricle. Unless otherwise specified, ATMs 
were collected from eAT. The eAT fat pads were collected, minced, and digested in 6 ml 
of 2 mg/ml type II collagenase (cat. no. C6885; Sigma) for 40 min at 37°C. The stromal 
vascular fraction (SVF) was separated from adipocytes by centrifugation followed by 
erythrocyte lysis with Ack buffer, as previously described71. The top adipocyte layer was 
transferred to a new vial and washed, then pelleted and stored at -80oC for either iron 
quantification or gene expression analysis. 
 
Cell staining with fluorescent antibodies 
 The SVF was treated with Fc block (BD) for 10 min and then stained with an 
appropriate combination of fluorophore-conjugated antibodies against cell-surface 
markers for 30 min at 4°C; F4/80-APC (eBioscience), F4/80-BV785 (BioLegend), 
CD11b-FITC (eBioscience), CD11b-APC/Cy7 (BD), CD45-BV605 (BioLegend), CD45-
PE (eBioscience), or CD163-CF594 (Antibody kindly provided by Dr. Soren Moestrup, 
Aarhus University; conjugated using the Mix-n-Stain CF594 kit; Biotium). Cells were 
washed in fluorescence-assisted cell sorter (FACS) buffer and filtered through filter-top 
FACS tubes to make a single-cell suspension.  
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Magnetic sorting with AutoMACS 
 Following staining and single-cell suspension (see Cell staining with 
fluorescent antibodies), cells were sorted by their ferromagnetic qualities through the 
sensitive positive selection (possel_s) program on the AutoMACS magnetic activated 
cells-sorting system (Milltenyl Biotech). After separation, the magnetic and non-
magnetic fractions were centrifuged at 500 g for 10 min at 4 °C. 
 
Flow cytometry and flow assisted cell sorting (FACS) 
 Cell stained with fluorescent antibodies were resuspended with a live/dead 
marker (DAPI or propridium iodide) and spiked with 50µl of CountBright counting beads 
(ThermoFischer Life Science). The samples were then analyzed in the Vanderbilt Flow 
Cytometry Shared Resource with either the LSRFortessa flow cytometer (BD 
Bioscience) or sorted with the FACSAria III cell sorter (BD Biosciences) with appropriate 
compensation controls and fluorescence minus one controls. Results were analyzed 
using FlowJo software v.10 (BD Biosciences), using gating previously published by our 
lab in the visual methods journal Jove109. The general gating scheme was: singlet cells 
! CD45+ ! live (PE or DAPI negative) ! F4/80+CD11b+ ! M1 or M2 markers. 
 
Iron injections 
 Mice were intraperitoneally injected with 5mg/kg Iron-100 (dextran conjugated 
solution, Durvet), diluted in 0.9% bacteriostatic sodium chloride solution (Hospira). 
Control groups received only intraperitoneal (IP) injection of the sodium chloride 
solution.  
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PKH26 cell stain 
 The PKH26 Red Fluorescent Cell Linker (Sigma) is selectively phagocytized by 
macrophages and neutrophils when they ingest the dye aggregate. The dye is resistant 
to metabolism and sustained in vivo for multiple weeks. This method can be used to 
stain all cells at a given time point. Following a wash-out period, any non-PKH cells are 
considered to be recruited after the time of injection. Twelve-week old mice were IP-
injected with 1ml of 5uM PKH26. Control groups were injected with an equal volume of 
the diluent. Following a 2-day wash-out period, mice were injected with either saline or 
iron (described in Iron injections). 
 
Iron staining with Prussian blue 
 Iron was visualized in section of paraffin-embedded eAT using the Perls’ 
Prussian blue staining method. The tissue was sectioned to 10µm onto glass slides, 
cleared, hydrated and stained with microwave-heated Prussian blue staining solution 
(10% hydrochloric acid, 10% Prussian blue) for 20 min, then counterstained with 
nuclear fast red for 5 min.  
 
Gene expression by quantitative real-time PCR (RT-PCR) 
 Macrophages were collected via FACS, as described above, pelleted and 
resuspended in RLT buffer to allow for RNA extraction with the RNeasy Micro RNA kit 
(Qiagen), according to the manufacturers instructions. Adipocytes were collected as 
described above, but the final pellet was collected in TRIzol reagent (Invitrogen) and 
isolated with the Direct-zol RNA MiniPrep kit (Genesee). For both macrophage and 
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adipocytes, cDNA was synthesized with the iScript cDNA synthesis kit (BioRad) and 
quantitative RT-PCR was performed with the Taqman assay system (Applied 
Biosystems) on a CFX96 cycler (BioRad). Gene expression was normalized to 
glyceraldehyde-3-phosphate dehydrogenase, and the control group, using the 2−∆∆Ct 
method.  
 
Glucose tolerance tests 
 Lean body mass of mice in the study was quantified using body composition 
values from the Minispec Model mq7.5 (Bruker). Glucose tolerance was determined by 
IP injection of dextrose at 2mg/kg lean mass. Blood glucose was subsequently tested at 
15-30 minutes intervals over two hours, using tail-vein blood and a handheld glucometer 
(ACCU-CHEK, Aviva Plus, Roche).  
 
Insulin injections 
 Insulin signaling was assessed by IP injection of 0.5U/kg of insulin or saline 
control 15 minutes prior to sacrifice. Tissues were flash-frozen to assess insulin-
response by Western blot quantification (see Western blot of AT and liver proteins).  
 
Serum iron and hormone parameters 
 Iron, Tf, Ft and total iron-binding capacity (TIBC) were quantified from serum 
using the ACE Alera clinical chemistry system (Alfa Wasserman). Adiponectin was 
quantified in plasma with the Milliplex MAP Mouse Adiponectin Magnetic Single Plex Kit 
(Millipore).  
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Cell iron quantification 
 Macrophages: Iron was quantified in ATMs with double-focusing sector field 
high-resolution inductively-coupled mass spectrometry (ICP-MS; ELEMENT II; Thermo 
Fischer Scientific, Bremen, Germany) equipped with ESI auto sampler, in the Vanderbilt 
Mass Spectrometry Core.  
 Adipocytes: The adipocyte fraction was collected and pelleted, as described 
above. For atomic absorption spectrometry (AAS), samples were homogenized in 100µl 
radioimmunoprecipitation assay buffer for bicinchoninic assay protein analysis, digested 
in 1:2 v/v ultra-pure HNO3, and further diluted in 2% nitric acid. Internal standardization 
was performed with bovine liver (184 µg Fe/g; National Bureau of Standards, Standard 
Reference Material, United States Department of Commerce, Washington, DC). To 
perform ICP-MS, samples were homogenized in 2% SDS RIPA buffer and an aliquot 
was collected to quantify protein concentration by BCA assay. The remaining sample 
was digest in ultra-pure HNO3 (1:3 v/v dilution) for 12 hours at 60oF, then diluted with 
milliQ water for ICP-MS quantification at the Vanderbilt Mass Spectrometry Core. 
Quantification of adipocyte iron was compared between ICP-MS and AAS, with no 
significant difference found between the two methods (data not shown). 
 
Western blot of AT and liver proteins  
 Western blotting was used to quantify protein expression in liver and eAT. 0.1g of 
tissue was digested in 500ul of 2% RIPA lysis buffer [50mM Tris-HCl pH 7.4, 150mM 
NaCl, 1% Triton-X, 2% SDS, 1mM EDTA, 10mM NaF, Na deoxycholate, 1mM PMSF, 
1mM Na orthovandate]. The sample was homogenized, and the supernatant collected. 
	   36	  
Total protein concentrations were determined with BCA assay, and concentrations were 
standardized and stored in NuPAGE LDS Sample Buffer (Invitrogen). For denaturation, 
samples were incubated for 30 minutes at 60oC, then cooled. Gel electrophoresis was 
performed with the NuPAGE Western Blot System with 4-12% Bis-Tris Gels 
(Invitrogen). Protein was transferred from the gel to 0.45um nitrocellulose blotting 
membrane (Amersham Protran, GE). The membrane was blocked with Odyssey 
Blocking Buffer. Primary antibodies were applied overnight at 4oC. Primary antibodies 
used in these studies were: Beta-actin mouse anti-mouse mAb (Cell Signaling 3700S), 
rabbit anti-mouse phosphorylated Akt (pAkt) (Cell Signaling 4060S), and rabbit anti-
mouse Akt (Cell Signaling 9272S). Secondary antibodies were applied for 1hr at RT, 
and included: 800CW goat anti-rabbit IgG and 680RD goat anti-mouse IgG (Licor). The 
blots were imaged on a Li-Cor Odyssey Infrared Imaging System and band intensities 
were quantified using Image Studio Lite software. 
 
Adipose tissue explants 
 Mice were sacrificed and eAT fat pads were collected and cut into 50-60mg 
pieces. Each piece was placed into a 48-well tissue-culture plate with 300µl of DMEM 
and 5% fetal bovine serum, at 37oC for the time specified in the experiment. For 
subsequent RNA analysis, explant pieces were collected and digested in TRIZol 
Reagent (described in Gene expression by quantitative real-time PCR). Otherwise, 
samples were digested with type II collagenase and analyzed by flow cytometry 
(described previously in this chapter).   
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Live animal hepatic fat quantification 
 Hydrogen MR spectroscopy was performed by the Center for Small Animal 
Imaging (Vanderbilt) using the 4.7T (31cm bore) Agilent (Varian). MR spectroscopy was 
used to quantify liver fat at 5 locations in mice under 0.5% isofluorane anesthesia.  
 
Triglyceride quantification 
 The left lateral liver lobe was flash-frozen at sacrifice. 60mg of tissue was 
digested in 3M KOH in 65% EtOH and incubated at 70oC for 1hr, and at RT overnight. 
After samples were diluted with 2M Tris-HCl pH 7.5, the Infinity Triglycerides Liquid 
Stable Reagent (Thermo Scientific) was added at 2:3 ratio for colorimetric quantification 
of total triglycerides at 500nm. 
 
Metabolomics 
 Single-cell samples from AT or from spleen were magnetically sorted and then 
macrophages were collected using FACS (methods previously described in this 
chapter). The cell pellet was flash frozen and provided to Metabolon (NC, USA) for 
analysis. Metabolon provided metabolic pathway and subpathway analysis.  
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Bone marrow derived macrophage (BMDM) differentiation and polarization 
 L929 media: L929 media is collected from serum-starved L929 cells because it 
is able to provide GM-CSF and other growth products to induce the differentiation of 
macrophages from bone marrow cells. This media is produced by growing up L929 cells 
into large flasks with 10% DMEM over a course of 14 days. The serum is collected 
twice, at confluency and 3 days later. These two serum collections are mixed 1:1 and 
frozen at -20oC for use in BMDM differentiation, as described.  
 Bone marrow collection: BMDMs were produced by collecting bone marrow 
from female C57BL/6J mice. Briefly, mice are sacrificed by isofluorane exposure and 
cervical dislocation. Long bones of the lower extremity are cleaned off and flushed with 
DMEM with 10% fetal bovine serum, 1% HEPES, and 1% penicillin-streptomycin (10% 
FBS DMEM). Following red blood cell lysis with Ack buffer, the cells are filtered through 
a 100um filter. The bone marrow is plated in tissue-culture treated plates for 6-8 days in 
10% FBS DMEM spiked with 14% of L929 media. The media is changed every 2-3 days 
and differentiation can be observed visually. At full differentiation and 70-80% 
confluence, BMDMs are dislodged and plated into experimental wells for polarization. 
 BMDM polarization: BMDMs are plated at 1 million cells/ml in 14% L929, 10% 
DMEM. For M2 polarization, the media is spiked with 10ng/ml IL-4 (R&D Systems) and 
10ng/ml  IL-13 (R&D Systems) for four days. For M1 polarization, the media is spiked 
with 10 ng/ml LPS (Sigma) and 100ng/ml IFNγ (R&D Systems) for 24 hours. For Mme 
polarization, the media is spiked with 30mM glucose, 0.4mM palmitic acid (Nu-check 
Prep, Inc.), and 10nM of insulin (Novolin R, Novo Nordisk) for 24 hours.  
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CD163 liposome treatments 
 Liposomes were produced by our collaborators Dr. Anders Etzerodt and Dr. 
Soren Moestrup (Aarhaus University, Denmark), as previously described110. These 
liposomes (CD163lipos) are polyethylene glycol (PEG)-coated long-circulating 
liposomes adapted to target CD163 via surface attachment of rat anti-mouse CD163 
antibody (E10B10, Cytoguide Aps, Denmark). CD163lipos were either loaded with 
calcein disodium salt (Sigma Aldrich), a fluorescent protein, or with the cytotoxin 
doxorubicin (dox). For calcein studies, 12-week old mice were injected one time with 
calcein-loaded CD163lipos (CD163lipo/calcein), or empty controls (CD163lipo/empty). 
After 24 hours, mice were sacrificed and their tissues were imaged using the Xenogen 
IVIS 200 bioluminescent and fluorescent imaging system (Vanderbilt University Institute 
of Imaging). Autofluorescent background signal from lipids was subtracted, to provide a 
final image of true calcein fluorescent signal.  
 For depletion studies, mice were injected twice over a 10 day time period with 
dox-loaded CD163lipos (CD163lipo/dox) or empty controls (CD163lipo/empty). Both 
liposome solutions were brought to a 0.67mM lipid concentration with sterile PBS and 
warmed to room temperature. Every third day, for four total injections, 26.7ul of the 
liposome solution per gram body weight was injected IP using a 22G single-use needle.  
In studies combining CD163lipo with iron injections, the iron-dextran was injected (as 
described above), three days following the first liposomes injection. As in the previous 
studies, this iron injection occurred one week prior to sacrifice and was flanked by 
CD163lipo injections in order to maintain depletion.  
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Mannosylated nanoparticle (MnNP) treatments 
 MnNPs were provided to us by Dr. Giorgio (Vanderbilt). For a technical 
explanation of the production of mannosylated micelles, refer to their publication111  
Briefly, micelles are composed of multifunctional polymers with three main parts: a 
hydrophobic / pH-sensitive  part, a siRNA condensing part, and a section that allows for 
addition of mannose to the end of polymer. The micelle is coated with mannose to be 
recognized by the mannose receptor (CD206) on phagocytic cells, initiating 
endocytosis.  
 siRNA and Cy5+ dsDNA: Dicer-substrate small inhibitory RNAs (siRNAs) (IDT 
146862759, 146862762, 146862765, 146862768, 146862771) or the negative 
scrambled control (51011908) were resuspended at 50nM in sterile-filtered TE buffer 
and frozen in aliquots at -20oC. For Cy5+ double-stranded (dsDNA) studies, a Cy5+ 
antisense strand (IDT, 151568383) was annealed to complementary DNA sense strand 
(IDT, 12213382) for 5 minutes at 95oC, then cooled for 1 hour. 
 MnNP preparation: 5mg of dry MnNP polymer was resuspended in EtOH to 
make a 3 mg/ml micelle stock. The required amount of stock was diluted with citric acid 
buffer (pH 4). The diluted micelle solution was sterile-filtered through 0.45µm filter and 
incubated with the correct ratio of siRNA at room temperature for 30 minutes. The ratio 
of siRNA or dsDNA to micelles was determined by the charge of the nucleotide chains. 
The micelle-siRNA mixture was diluted with 10mM sodium phosphate buffer (pH 8). 
siRNA-loaded MnNPs were directly added to BMDMs in culture for up to 48 hours.  
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Statistical analysis 
All graphical data are presented as mean ± SEM. Statistical tests were performed using 
GraphPad Prism (La Jolla, CA) by two-tailed unpaired t tests and one-way ANOVA with 
the Tukey correction for multiple comparisons, when appropriate. In experiments with a 
2 x 2 design, two-way ANOVA’s were applied to determine significant variables and the 
impact of each factor.  
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CHAPTER III 
 
MFehi ATMs COMPENSATE FOR TISSUE IRON PERTURBATIONS 
 
This chapter represents work that has been accepted for publication in the American 
Journal of Physiology – Cell Physiology, by Hubler, Erikson, Kennedy, and Hasty112. 
 
Introduction 
 In order to respond to metabolic demand appropriately, adipocytes are in 
reciprocal communication with other tissues via systemic hormones (e.g. insulin, leptin, 
adiponectin). Under normal conditions, adipocytes are able to metabolize, store, and 
synthesize lipids without lipotoxicity80. Within the last decade, interest in AT has 
expanded as it becomes clear that local adipocyte physiology, such as oxidative stress 
or inflammation levels, can have beneficial or detrimental effects systemically.  
 ATMs are intercalated throughout the tissue matrix in close contact with 
individual adipocytes. ATMs were first identified in the context of obese AT, where 
metabolically-inflamed ATMs (Mme, described by Kratz30) accumulate and induce 
chronic inflammation 26, 94, 113. However, resident ATMs are also present in lean AT and 
fall on the anti-inflammatory (M2-like) end of the polarization spectrum. Understanding 
the homeostatic functions of resident M2-like ATMs in lean AT may provide a 
mechanism by which to influence the adipocyte microenvironment, supporting healthy 
AT expansion.  
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 To briefly review, macrophages are the primary cell responsible for handling iron 
in the body. Due to its scarcity, iron is recycled, primarily through the erythrocyte 
hemoglobin cycle114. Senescent erythrocytes are phagocytized and their heme-
associated iron is released as transferrin-bound iron. In fact, the transferrin-iron pool 
turns over several times daily in humans. Kupffer cells and splenic macrophages are 
primarily responsible for this turnover, which is regulated by hepcidin114. M1-like 
inflammatory macrophages have an important iron-sequestration role during infection. 
However, the field has expanded its understanding of macrophages in iron homeostasis 
beyond just M1-like macrophages in blood, to include resident M2-like macrophages in 
tissues. Iron is now thought to be spatially regulated on a microenvironmental scale in 
muscle, spinal cord, and vasculature, and even regulated in a time-dependent manner 
during wound repair90, 98, 115. In these studies, resident M2-like macrophages are 
responsible for fine-tuned iron uptake and release. Similarly, regulated control of iron 
homeostasis is important in AT because AT requires iron availability for healthy 
adipogenesis17 and because excess fatty acids in AT can react with free iron to facilitate 
a lipid peroxidation chain reaction116. Studies have shown that iron overload, specifically 
in adipocytes, can reduce systemic insulin sensitivity through a reduction in 
adiponectin17, 117. This emphasizes the importance of tight regulation of iron in AT – 
providing the impetus to assess the role of macrophages in this process. 
 As described in the Chapter I, “MFehi” ATMs were discovered by our lab as 
resident macrophages of the AT that have innate ferromagnetism due to high 
intracellular iron content71. Like all macrophages in lean AT118, their cell surface protein 
profile is representative of an M2-like, alternatively activated macrophage71. This is in 
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contrast to M1 classically activated inflammatory macrophages, or Mme, the 
metabolically activated macrophages, that infiltrate AT in obesity. Macrophage 
polarization is useful for generic classification but, in vivo, macrophages span a 
spectrum of activation states119. Studies have shown that macrophage polarization 
strongly influences their iron handling – broadly, M2 macrophages have an iron-cycling 
phenotype, preferring iron uptake and release over inert storage96, 97, 106, 120. Although all 
ATMs in lean AT are M2-like, when they are sorted out by ferromagnetic qualities, MFehi 
ATMs were found to have an even stronger M2 expression pattern relative to other 
resident M2 “MFelo” ATMs. Reflecting this iron-cycling phenotype, MFehi have increased 
expression of iron-uptake associated genes. However, unlike M2 macrophages 
polarized in vitro, MFehi ATMs have higher cellular iron content. Therefore, even though 
MFehi ATMs have an M2-like iron-cycling phenotype based on their gene expression, 
their increased iron content is more reflective of M1-like ATMs. This contrast presents 
an opportunity to better understand the specific functional role for MFehi ATMs in 
regulating adipose tissue iron2. We hypothesized that MFehi cells respond to iron 
perturbations in AT by regulating their intracellular iron pool in response to iron in the 
microenvironment, and that this function is necessary to prevent adipocyte iron-loading 
when excess iron is present.  
 To test this hypothesis we looked at the response of MFehi ATMs, MFelo ATMs 
and adipocytes in the context of two conditions of high iron: dietary iron and iron 
injection. Our studies demonstrated that MFehi ATMs increase their intracellular iron 
content, upregulate iron-handling genes, and recruit macrophages, both from the MFelo 
population and from the circulation, as a compensatory response to excess iron.   
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Results 
MFehi ATMs accumulate iron with high-iron diet 
 Based on the described MFehi ATM iron-cycling phenotype, we hypothesized that 
MFehi ATMs would respond to changes in iron concentrations in the AT environment. 
We sought to determine if MFehi ATMs would respond to systemic changes in iron 
through a high-iron diet. After 8 weeks on low-, average-, or high-iron diet, we noted 
systemic iron overload with increased serum iron and Tf saturation (Fig 3.1A & B, 
p<0.0001), but no change in hematocrit (Fig. 3.1C). Dietary iron caused no changes in 
weight gain, body composition, or glucose tolerance (Fig. 3.1D - F). Iron-laden cells 
were seen by Prussian-blue staining (Fig. 3.2A). Using ICP-MS quantification, iron 
content per cell positively correlated with dietary iron (Fig. 3.2B; p<0.01 35ppm vs. 
2000ppm; p<0.05 500ppm vs. 2000ppm). There was also a significant increase in the 
count of MFehi ATMs from low-to-average-to-high iron, with 7.6 x 104, 1.1 x 105, 1.5 x 
105 per gram tissue, respectively (Fig. 3.2C; p<0.05 35ppm vs. 500ppm; p<0.05 
500ppm vs. 2000ppm; p<0.001 35ppm vs. 2000ppm). Neither MFelo ATMs nor 
adipocytes had an increase in iron content (Fig. 3.2C & D). Adipocyte iron was 
quantified using both AAS and ICP-MS methods to ensure rigor and reproducibility of 
this finding, with no significant differences between the two methods (data not shown).  
The size of the adipocytes was 1017±103, 1004±22, and 946±97 µm2, low-to-high iron 
respectively, with no significant difference between the groups. 
	   46	  
 
 
 
 
 
  
Figure 3.1. Physiological and serum iron parameters from mice on iron diets. C57BL/6J mice were 
given 8 weeks of low (35ppm), average (500ppm), and high (2000ppm) iron diets. Serum iron 
parameters such as (A) serum iron (N=5), (B) transferrin saturation calculated as % iron/TIBC (N=4-6), 
and (C) hematocrit (N=6) were quantified. (D) Body weight was recorded over the study course (N=18-
22). (E) Body composition (N=6) and (F) glucose tolerance tests were performed after 8 weeks on diet 
(N=6). For all studies, significant differences were identified using ANOVA and t-test, with the following p-
value indicators: ***p<0.001, ***p<0.0001. 
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Figure 3.2. Effect of 8 weeks of iron diet feeding on ATM and adipocyte iron content. C57BL/6J 
mice were on 8 weeks of low (35ppm), average (500ppm), and high (2000ppm) iron diet. (A) Whole AT 
was fixed and sectioned, then stained with Prussian blue to visualize iron and counter-stained with 
nuclear fast red. Cells were sorted in order to quantify (B) iron content per ATM (N=8-10), (C) ATMs per 
gram of tissue, and (D) adipocyte iron content (N=8-10). For all studies, significant differences were 
identified using ANOVA and t-test, with the following p-value indicators: *p<0.05, **p<0.01, ***p<0.001. 
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MFehi respond to high dietary iron by upregulating iron-storage genes 
 MFehi, MFelo, and adipocytes were collected for gene expression from mice fed 
varying levels of dietary iron to assess the cells’ response to iron availability. Expression 
of iron uptake genes Cd163 and Tfrc, iron processing Hmox1, and iron export, Slc40a1, 
were greater in MFehi ATMs compared to MFelo ATMs across all concentrations of 
dietary iron (Fig. 3.3). Furthermore, MFehi were generally more M2-polarized, with less 
expression of Itgax and Nos2 compared to MFelo. In response to excess dietary iron, 
the MFehi population had an increase in expression of iron storage-associated genes 
Ftl1 and Fth1, significant by 2-way ANOVA with a p<0.01 between cell types, and 
p<0.05 between diets (Fig. 3.3). Lastly, in response to high dietary iron, the MFehi 
population expressed higher levels of Spic, the transcription factor required for the 
development of iron-handling macrophages in the spleen and bone marrow60. In 
contrast, MFelo ATMs had no change in iron-handling gene expression levels due to 
increased iron (Fig. 3.3A - J). Similarly, there was no difference in adipocyte iron-
handling genes upon dietary iron challenge, although a trend for an increase in Ftl1, 
Fth1, and Il6 was noted (Fig. 3.4A - F). Importantly, Adipoq expression was not different 
between groups (Fig. 3.4G). 
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Figure 3.3. Effect of 8 weeks of iron diet feeding on ATM gene expression. C57BL/6J mice were on 
8 weeks of low (35ppm), average (500ppm), and high (2000ppm) iron diet. Iron-handling genes were 
quantified by RT-PCR for MFelo and MFehi ATMs (N=4-5). Results are normalized to MFelo expression in 
the average (500ppm) iron diet. For all studies, significant differences were identified using ANOVA and 
t-test, with the following p-value indicators: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 3.4. Adipocyte gene expression after 8 weeks on iron diets. C57BL/6J mice were on 8 weeks of 
low (35ppm), average (500ppm), and high (2000ppm) iron diet. Iron-handling genes were quantified by RT-
PCR (N=4-5). For all studies, significant differences were identified using ANOVA and t-test. 
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Excess peritoneal iron is taken up by ATMs, not by adipocytes 
 Iron absorption is regulated through the intestinal tract, so diet-mediate iron 
overload is somewhat limited by a feedback-regulated maximum absorptive capacity. IP 
iron administration provides a direct way to provide higher iron levels to the peritoneum. 
This method was used to demonstrate the proof-of-concept that ATMs compensate for 
excess iron, as IP iron administration circumvents some of the systemic and absorption 
limitations of iron-diet models. In iron-injected mice, there was a visible increase in SVF 
iron content by Prussian blue staining (Fig. 3.5A). MFehi had a significant increase in 
intracellular iron content (p<0.01), while MFelo ATM iron content did not change (Fig. 
3.5B). Interestingly, the number of MFelo cells per gram eAT was decreased (by 
6.7x104; p<0.02), while conversely, the number of MFehi cells per gram eAT was 
increased (by 1.3x105; p<0.0001; Fig. 3.5C). Most importantly, adipocyte intracellular 
iron, quantified by both AAS and ICP-MS, was not altered by the acute high-dose 
injection of iron (Fig. 3.5D).  
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Figure 3.5. Effect of iron injection on ATM and adipocyte iron content. C57BL/6J mice were given an 
IP injection of 5 mg/kg iron dextran 1 week prior to sacrifice. (A) Whole AT was fixed and sectioned, then 
stained with Prussian blue to visualize iron and counter-stained with nuclear red. Cells were sorted in order 
to quantify (B) iron content per ATM (N=6), (C) ATMs per gram of tissue (N=7), and (D) adipocyte iron 
content (N=18). For all studies, significant differences were identified using ANOVA and t-test, with the 
following p-value indicators: *p<0.05, ****p<0.0001. 
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MFehi ATMs respond to acute high iron with alterations in iron-handling genes 
 The MFehi ATMs demonstrate changes in their iron-related gene expression in 
response to excess iron. Iron-import genes, Cd163 (p=0.01) and Tfrc (p=0.001) 
decreased, while the iron-storage gene Fth1 (p=0.01), iron-metabolism gene Hmox1 
(p=0.01), and the iron-export gene Slc40a1 (p<0.0001) were all increased (Fig. 3.6A -
F). Interestingly, in ANOVA analysis comparing the effect or the iron injection to the cell 
type, the iron effect drove the significant difference for all genes except Fth1. This is in 
contrast to MFelo, which showed no significant difference in any of the iron-handling 
genes in response to IP iron (Fig. 3.6A - F). Adipocytes did not have significant changes 
in the iron handling genes Fth1 or Ftl1 (although there was a trend toward an increase), 
reflecting their unaltered iron content (Fig. 3.7C - D). But adipocytes did have an 
elevation of Hmox1 (p=0.01) and Slc40a1 (p<0.01) (Fig. 3.7B, E). Importantly, Adipoq 
and Il6, indicators of inflammation and dysfunction in adipocytes, were unchanged (Fig. 
F & H). 
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Figure 3.6. Effect of iron injection on ATM gene expression. C57BL/6J mice were given an IP injection 
of 5 mg/kg iron dextran 1 week prior to sacrifice. Iron-handling genes were quantified by RT-PCR for MFelo 
and MFehi ATMs (N=6). For all studies, significant differences were identified using ANOVA and t-test, with 
the following p-value indicators: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 3.7. Effect of iron injection on adipocyte gene expression. C57BL/6J mice were given an IP 
injection of 5 mg/kg iron 1 week prior to sacrifice. Adipocytes were isolated, RNA prepared, and iron-
handling genes quantified by RT-PCR (N=6). For all studies, significant differences were identified using 
ANOVA and t-test, with the following p-value indicators: *p<0.05, **p<0.01. 
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Addressing increased MFehi counts following iron injection 
 Increased MFehi counts can be explained by three mechanisms: (1) Monocytes 
are recruited and become MFehi ATMs, (2) MFelo ATMs take up enough excess iron to 
essentially convert into MFehi cells, or (3) MFehi ATMs undergo cellular proliferation. We 
used the cell tracer PKH26 to address the first two possibilities. PKH26 is readily taken 
up by phagocytic cells and can be used to mark resident macrophages. Any PKH26-
stained (PKH+) cells detected at the end of the study must have been present at the 
time of PKH26 injection. In contrast, an increase in PKH26-negative (PKH-) cells 
represents monocyte-derived macrophages recruited after the time of PKH26 injection. 
Reciprocal changes in counts of PKH+ MFehi or MFelo ATMs could indicate a shift 
between the two populations. We combined PKH26-mediated cell tracing with the 1-
week iron injection model to understand whether changes in the ATM cell counts were 
due to shifts in iron-containing populations or due to monocyte recruitment. At 1 week 
post iron-injection, 78% of all macrophages were PKH+. The count of resident PKH+ 
MFelo ATMs decreased by 7.1x104 cells/gram tissue and PKH+ MFehi ATMs increased 
by 1.1x105 cells per gram tissue (Fig. 3.8A). This shift accounted for 83% of the total 
difference in MFehi (Fig. 3.5C). Of the recruited PKH- ATMs, there was no difference in 
MFelo ATMs. Interestingly, almost no MFehi macrophages were recruited in the absence 
of iron injection; however, 2.0x104 PKH- MFehi ATMs/gram tissue were recruited upon 
iron injection (Fig. 3.8B, p<0.01). Based on these results, monocyte recruitment 
accounts for 17% of the increase in MFehi in response to iron injections. Thus, our PKH 
studies reveal that shifts in ATM populations from MFelo to MFehi ATMs and monocyte 
recruitment fully account for the increase in MFehi following iron injection.  
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Iron uptake by ATMs is associated with M2-polarization 
 MFelo incorporation into the ferromagnetic fraction accounts for the majority of 
the increase in MFehi population following iron injection. Because the MFelo have 
reduced M2-like phenotype compared to MFehi, we hypothesized that their incorporation 
into the MFehi pool would shift the overall polarization state of the MFehi population to 
lower relative expression of M2-associated proteins. However, the opposite was true; in 
iron-injected mice, the MFehi ATMs had a decrease in cells positive for inflammation-
associated surface markers (CCR2, CD11c) and an increased in cells with M2-
associated marker, CD206 (Fig. 3.8E). In contrast, there was a decrease in the count of 
MFelo ATMs positive for CCR2 and CD11c, and no change in CD206 (Fig. 3.8C-E). The 
findings indicate that iron uptake does not drive an inflammatory profile in macrophages 
MFehi cells, while it does in MFelo. Thus, even with MFelo incorporation into the MFehi 
population, the MFehi profile is even more M2-like post iron-injection.  
  
	   58	  
  
Figure 3.8. Effect of iron injection on ATM inflammatory markers and recruitment. ATMs were 
marked with PKH26 prior to iron injection to assess for population shifts as quantified by the (A) resident 
PKH+ ATMs, and monocyte recruitment as quantified by (B) PKH- ATMs (N=7). MFehi and MFelo 
polarization response to iron injection was quantified by cell surface inflammatory markers, including M1-
associated (C) CCR2 and (D) CD11c, as well as M2-associated (E) CD206 (N=4-6). For all studies, 
significant differences were identified using ANOVA and t-test, with the following p-value indicators: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Discussion 
 Reflecting the field’s current interest in macrophage polarization and iron 
handling by tissue-associated macrophages, we challenged MFehi ATMs with excess 
iron to investigate their functional role in maintaining AT iron levels. We approached this 
by supplying iron through a dietary route as well as direct IP injection. Dietary iron 
provision has commonly been used in other studies, often over a course of 8 weeks, 
and with non-heme sources of iron, because mice cannot absorb heme iron121. While 
systemic iron loading does occur consistently in dietary iron studies, the metabolic 
impact has been variable. McClain et al. provided high-, normal- and low-iron diets 
(20,000 mg/kg, 330 mg/kg, and 7 mg/kg carbonyl iron, respectively) to C57BL/6 mice for 
8 weeks and observed a 40% decrease in Tfrc in adipocytes, 30% decrease in Adipoq, 
and an overall decrease in fat mass and increase in lean mass. These changes were 
associated with increased oxygen consumption by high-iron diet mice, and were 
adiponectin-dependent. However, in our studies, we so no impact of dietary iron on 
body weight or fat mass. We also noted no impact on glucose tolerance or difference in 
adipocyte gene expression. The most likely explanation for this difference is that our 
high-iron diet model had 10-fold lower iron than the McClain study. To confirm iron 
loading, we quantified serum iron and Tf saturation. The increased iron levels were 
supported by the increased iron content in MFehi ATMs themselves. We recognized that 
the adipocyte iron content had high variability. This may be due to the need to 
standardize the iron quantification to cellular protein. Furthermore, variability in 
adipocyte iron content appears to be a common finding in this type of study84. A second 
concern with this technique is the possibility that high-iron adipocytes are lost during the 
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adipocyte collection process, selecting for adipocytes that are not iron loaded. However, 
at this time, there are no alternative methodologies for collecting adipocytes. Even given 
these limitations, our studies highlight the fact that MFehi macrophages in AT appear to 
serve as an iron-sink during chronic iron exposure. 
 We were interested in the proof-of-concept that MFehi ATMs accommodate for 
excess iron. Therefore, we gave iron-dextran at supra-physiological doses. Even as a 
model of excess iron, iron-dextran injection is medically relevant, as both iron-dextran 
and superparmagnetic iron oxide nanoparticles have been commonly used in humans 
to treat anemia, and interestingly, accumulate in AT122, 123. Iron-dextran is processed in 
a similar manner to hemoglobin iron, and has not been associated with cardiac 
dysfunction in C57BL/6 mice, presumably because they are able to excrete some of the 
excess iron in the feces124. The type of iron processed by macrophages also influences 
their phenotype and could explain some of the contradictions between studies 
describing “iron-cycling” macrophages in vitro and in vivo. In tissues closely associated 
with the reticular system such as spleen, vasculature, and muscle, heme-associated 
iron is abundantly recycled by macrophages. Heme uptake liberates ferrous iron, and 
M2 macrophages respond by enhancing their oxidative stress pathways, Hmox1, and 
Fpn125. In fact, CD163hi macrophages (Mhem) have been described as being protected 
from oxidative stress and less prone to lipid accumulation126. In these systems, the 
recycling of iron from heme can be provisional to red blood cell production or wound 
healing and the degradation process is inherently anti-inflammatory. However, most in 
vitro studies of macrophage iron handling have been performed with sources of ferric 
iron or Tf-bound iron. AT is known to have very low levels of hemolysis. Therefore, we 
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postulated that Tf-bound iron is the primary source of iron for macrophages - whether 
from serum or adjacent cells - but this area warrants further analysis.   
 Macrophages have been coopted by many tissues to perform homeostatic 
functions outside of their typical immunological role. What is especially unique about 
these functions is that they allow for fine-tuned hemostatic regulation in tissues, often 
uncoupled from systemic physiology. For example, Corna et al. used a macrophage-
specific Fpn1-knockdown model in muscle damage115. Even though the macrophages 
became iron-loaded, they still accumulated at the site of damage and did not become 
oxidatively stressed. Importantly, in this model of impaired macrophage iron export, 
myofiber regeneration was limited115. Furthermore, changes in expression levels of iron-
associated genes in the muscle were not associated with changes in systemic iron 
homeostasis, indicating that there was an independent micro-environmental 
homeostasis between the tissue and resident macrophages. Similarly, in human 
atherosclerotic plaques, M2 macrophages process the iron released from hemolysis90. 
Our results indicate that ATMs respond to excess iron, preventing iron overload in 
adipocytes. Even though adipocytes had increased expression of Slc40a1, the gene for 
the iron exporter Fpn1, and trends in Fth/Ftl, they had no increase in intracellular iron or 
inflammatory markers. So, even if the adipocytes did uptake iron, they were able to 
release this iron, likely to be taken up by MFehi. Interestingly, with acute iron injection 
the MFehi had an M2-like iron cycling phenotype (i.e. increased Tfrc, Slc40a1) (Fig. 3.6), 
whereas, in the chronic iron diet studies, MFehi mainly had increased expression of M1-
like iron-storage genes Fth1/Ftl1 (Fig. 3.3). However, in both contexts, MFehi ATMs 
	   62	  
accrued higher levels of iron. This may indicate a temporality to the response of these 
ATMs to take up and store iron effectively.  
 The functional adaptability of macrophages has been linked to their phenotypic 
flexibility. Generally, the polarization state of macrophages is associated with different 
responses to iron – M1 macrophages dogmatically sequester iron as a bacteriostatic 
mechanism, and M2 macrophages take up and release iron quickly. Studies have 
demonstrated that iron handling by macrophages can be impacted simply by altering 
their polarization stimuli96, 97. However, there is a complex and reciprocal relationship 
between the phenotype of macrophages and their response to iron. For example, when 
macrophages are iron-loaded due to Fpn1 deficiency, they respond to inflammatory 
stimulation with increased inflammatory cytokine expression127. This effect is iron-
dependent, as it can be ameliorated in the presence of an iron chelator127. In contrast, 
iron-loaded M2-polarized macrophages have high expression of iron uptake and iron 
export genes, even in the presence of excess iron96. The shift in iron handling gene 
expression can be tied back to a change in the binding of IRPs in response to iron 
levels113. In human M2-polarized macrophages, simply chelating intracellular iron can 
shift M2 macrophages from an iron-cycling phenotype (higher import/export genes) to 
an iron-storage phenotype (higher Ft)120.  
 Some of these differences are also seen in vivo. For example, the M2-polarized 
macrophages seen in atherosclerotic plaques have an iron-cycling profile, and they are 
quick to release iron rather than accrue it90. The “iron-cycling” phenotype has been 
shown to play an important role in certain tissues because the macrophages can take 
up and release iron as needed. Considering these findings, it is surprising that the iron-
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storing MFehi ATM population is not only very strongly M2-polarized, but also maintains 
this polarization even while accumulating iron. We noted that MFehi ATMs were able to 
take up and sequester the excess iron provided through diet or injection, in line with the 
macrophage response in muscle damage, in which Fpn knockout macrophages load 
iron, even without oxidative stress115. In fact, the M2 macrophage phenotype in tissues 
may be more complex than the stereotypical iron-handling dichotomy described for M1 
and M2. We observed an increase in Fth in response to iron injection, reflecting a 
protective response by MFehi ATMs. Furthermore, even with iron loading, MFehi ATMs 
did not take on a more inflammatory profile. This contrasts studies in liver and alveolar 
macrophages, where iron loading of macrophages is associated with increased 
inflammation 128.  
 Indeed, comparing resident macrophages from different tissues highlights the 
adaptability and specification of macrophages. Our understanding of the iron-cycling 
phenotype of the MFehi ATMs is limited by our inability to assess iron-related proteins 
specifically in these cells due to their low numbers. This restricts us to the use of flow 
cytometry and gene expression to assess the phenotype of the cells, rather than 
Western blot. In future studies, it would be ideal to develop a method for assessing iron-
response protein levels because a cell’s iron response is primarily driven through the 
iron-response protein system, such that levels of these proteins is the most sensitive 
and accurate way of determining the iron status of a cell.  Despite this limitation, the 
observation that MFehi take up excess iron and yet remain M2 polarized suggests a 
specialized function for this unique cell population.  
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 Following iron injection, there was an increase in MFehi per gram of tissue, with a 
reciprocal decrease in MFelo. Increased MFehi were also observed with iron diets, but 
the effect was more subtle. In fact, PKH26 staining of resident macrophages allowed us 
to deduce that the enlarged MFehi population was likely due to MFelo cell “conversion” to 
MFehi. The MFehi population is defined by positive magnetic sorting, but relative to 
MFelo, MFehi were also found to have extreme M2-polarization by gene expression and 
flow cytometry71. With more cells adhering to the magnet, we cannot conclude if the 
uptake of iron by MFelo represents a conversion in ATM subtypes, or simply acquired 
paramagnetic qualities of MFelo who have taken up excess iron.  
 There are no known methods that would allow us to trace MFehi versus MFelo. 
However, we would predict that if the MFehi population became enriched with MFelo, the 
average polarization profile would shift away from the extreme M2-polarization. MFehi 
are on average more M2-polarized with iron uptake – even with newly incorporated 
MFelo cells. This suggests that the MFelo cells incorporated into the MFehi pool are not 
simply paramagnetic but may be changing their actual phenotype and function. This 
contradicts other studies that show inflammatory polarization of macrophages with iron 
treatment. Therefore, we hypothesize that a unique conversion of macrophages may be 
occurring with excess iron in adipose tissue. Interestingly, we noted an increase in the 
expression of the developmental transcription factor Spic in MFehi in our iron diet 
studies. This may demonstrate a mechanism by which either MFelo ATMs or recruited 
monocytes are converting to the MFehi phenotype.  
  Our studies further explore a role for a subtype of ATMs in taking up and 
processing iron to protect adipocytes from iron overload. Using dietary and IP iron 
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overload we demonstrated that MFehi ATMs are able to fully compensate for excess iron 
in the AT. As part of this response, the MFehi pool expands to include iron-loaded MFelo 
that have shifted to a stronger M2-phenotype. Furthermore, circulating monocytes are 
also recruited to the MFehi pool. These findings expand our understanding of iron-
handling by macrophages beyond the classic M1/M2 paradigm. In conjunction with 
other studies in the field, this further demonstrates the importance of fine-tuned iron 
regulation for adipocytes, and the intimate homeostatic relationship between 
macrophages and adipocytes. It is thought that iron release by M2 macrophages allows 
for cellular proliferation. For example, in co-culture studies, media from human M2-
polarized cells supported cancerous growth, and this effect was reversible with iron 
chelation97. Similarly, studies have shown that iron is necessary for adipogenesis77. 
Therefore, future studies in this area will look at the interaction of resident macrophages 
in AT and their role in iron homeostasis in the context of adipogenesis.   
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CHAPTER IV 
 
MFehi IRON HANDLING AND THE DIET-INDUCED OBESITY MODEL 
 
Introduction 
 Feeding HFD to C57BL/6J mice is a common and useful model of obesity 
because the mice respond to the excess dietary fat with weight gain, hyperinsulinemia, 
hyperglycemia, and hypertension129. Hyperglycemia occurs within four weeks of HFD, 
and adipocyte hypertrophy and hyperplasia continue up to 16 weeks of diet28. Strissel et 
al. studied AT over a course of 20 weeks in C57BL/6J mice on 60% HFD. They noted 
that adipocyte death correlated with AT expansion and M1-like polarization of ATMs, in 
conjunction with matrix deposition and adiponeogenesis28. Considering that 
adipogenesis is also a time of  high iron-need by adipocytes, it is of interest to 
understand how MFehi macrophages may be playing a role in the timing of AT 
remodeling. In Strissel’s paper, AT remodeling at 18 weeks of HFD in C57BL/6J mice 
occurred only in eAT, not subcutaneous AT (Fig. 4.1). While adipocyte death increased 
progressively up to 20% at 14 weeks of diet, at 16 weeks, dying adipocytes jumped up 
to nearly 80%, then dropped down to 20% again at 20 weeks of diet28 (Fig. 4.1A). 
Furthermore, the loss of eAT mass starting at 16 weeks of diet was associated with an 
increase in liver hepatosteatosis28. Others in the field have postulated a connection 
between hepatic iron and lipid metabolism130. For example, iron deficiency in rats was 
associated with increased hepatic triglyceride (TG) accumulation131. While lipid storage 
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changes over time on HFD in AT and liver, no studies have been conducted to 
associate the lipid storage over time with iron content in both of these tissues.  
Just as macrophages have homeostatic functions in lean AT, they play an important 
role in AT remodeling in obesity. In obesity, ATMs are found around necrotic adipocytes 
in formations called crown-like structures, forming a syncytia that develops into a 
multinucleated giant cells, a classic indication of chronic inflammation27.  
 Considering the impact of obesity on nearly every aspect of AT function, it is 
natural to suspect that the ferrostatic function of MFehi ATMs, described in Chapter III, 
may be impacted by obesity. Changes in iron handling by ATMs in obesity would be 
especially significant in relation to DIOS. DIOS is based on studies in humans 
correlating high ferritin levels, a marker for iron load, with metabolic syndrome47. 
Considering that adipocytes are already oxidatively stressed with excess lipids in 
obesity, altered iron availability could have an additive detrimental effect on adipocytes. 
This was evident in the adipocyte-specific iron overload model in mice, that led to 
systemic metabolic dysfunction, due to reduced adiponectin release17.  
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Figure 4.1. [Adapted from Strissel et al. 200728] Adipose tissue remodeling over 20 weeks of HFD 
in C57BL/6J mice. (A) Dead adipocytes in visceral AT (eAT) and subcutaneous AT (iAT). (B) Adipocyte 
cell numbers over 1-20 weeks of HFD. (C) There exists an inverse correlation between eAT weight and 
liver weight. 
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  Adipocytes have a four-fold increase in adipocyte iron content in 16 week HFD-
induced obese mice71 (Fig. 4.2A). In contrast, in the liver, there is a 50% reduction in 
iron. Adipocytes also had altered gene expression that corresponded with iron-storage: 
decreased Tfrc, increased Hmox1, Fth1, Ftl1, and a trend toward decreased Slc40a1, in 
conjunction with decreased Adipoq (adiponectin) expression (Fig. 4.2C). In contrast to 
adipocytes, MFehi ATMs had reduced intracellular iron content in obesity. Their gene 
expression profile was more reminiscent of a M1-like macrophage, with higher levels of 
Ft, and decreased iron-uptake and release genes (Fig. 4.2). Orr et al. also 
demonstrated that monocytes recruited during HFD-induced obesity were incorporated 
into the MFelo population, and the MFehi population remained the same size71.  
 The observed changes in tissue iron in response to diet-induced obesity aligns 
with the theory of DIOS in humans. Furthermore, alterations in MFehi iron suggest that 
MFehi function may be impaired in obesity, which could underlie the observed increases 
in adipocyte iron. To address this hypothesis, we applied the same IP iron injection 
model as in Chapter III, but in diet-induced obese mice. The combination of iron 
injections and obesity allowed us to probe the ability of MFehi ATMs to compensate for 
excess iron in the inflammatory state of obesity.  
 Specifically, we hypothesized that obesity would impair iron uptake by MFehi 
ATMs, thereby leading to adipocyte iron loading and reduced adiponectin expression. 
We explored possible mechanisms underlying this effect, including arginine metabolism 
and oxidative stress. Studies from our lab have shown that some of the major 
metabolite profiles differentiating MFehi from MFelo could be traced back to the arginine 
metabolism pathway (Fig. 4.3). Therefore, when considering the impact of HFD-
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associated inflammation on MFehi ATMs, arginine metabolism is of particular interest. 
Arginine catabolism has been shown to play a defining role in M1/M2 polarization of 
macrophages in general132. Under Th1 stimulation, arginine is metabolized by inducible 
nitric oxide synthase (Nos2) to make nitric oxide (NO). Under Th2 stimulation, arginine 
is metabolized by arginase to make urea and ornithine. This system is regulated by 
arginine availability through the cationic amino acid transporter (CAT2). Furthermore, 
arginine deficiency in either context could lead to production of superoxide radicals, 
which would be an especially potent oxidative stressor in the presence of iron133, 134.  
 Oxidative stress is thought to play a role in macrophage polarization in obesity135, 
136. Furthermore, inappropriate iron handling by cells can lead to oxidative damage. This 
motivated us to explore markers for antioxidant response in MFehi and MFelo in 
response to diet and iron injections. Nrf2 (Nfe2l2) is a transcription factor that regulates 
the expression of many antioxidant proteins137. In its inactive form, it stays in the 
cytoplasm, bound by Keap1 (Keap1), and its levels are regulated by ubiquitination and 
degradation138. Therefore, while gene expression levels of Nfe2l2 may not reflect the 
oxidative state of a cell, Keap1 levels can reflect regulation of the cell’s antioxidant 
response137.  
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Figure 4.2. [Adapted from Orr et al. 201373] Adipocyte liver and ATM response to 16 weeks of 
HFD. (A) Adipocyte iron content was quantified with AAS. (B) Liver iron content quantified by AAS. (C) 
Adipocyte iron-handling gene expression, from LFD-fed and HFD-fed mice. (D) Iron quantified by ICP-
MS in ATMs from lean and obese mice. (E) Iron-handling gene expression in MFehi from lean or obese 
mice. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001  
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Figure 4.3. Arginine catabolism in the context of MFehi and MFelo. (A) [Adapted from Hesse et al. 
20011]  Schematic of Th1 and Th2 stimuli impacting arginine catabolism pathways, (B) Model of 
hypothesized arginase metabolism between MFelo and MFehi, based on results of (C) metabolomics 
studies comparing MFelo and MFehi from lean and obese mice, as well as high- and low-iron cells from the 
spleen. 
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 In the following studies we aimed to understand the impact of obesity on iron-
handling by MFehi ATMs. We found that obesity does not impact the ability of MFehi to 
take up iron, but the “iron-cycling” phenotype is blunted. We also – unexpectedly – 
observed no increase in adipocyte iron content in obesity. This lead to  further set of 
studies investigating the time course of AT and liver lipid and iron storage over 20 
weeks of HFD. However, no significant differences were observed. Even with 
unexpected results in these specific studies, the methodologies outlined in the following 
studies set the stage for further evaluation of MFehi function in obese AT.  
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Results 
Iron is taken up by MFehi in obesity 
 C57BL/6J mice were placed on 10% LFD or 60% HFD for 16 weeks, with a final 
weight difference of 20g (Fig. 4.4). One week prior to sacrifice, both groups were split in 
a weight-matched subgroups and injected once with iron-dextran.  
 AT sections stained with Prussian blue demonstrate iron uptake in cells 
intercalated between adipocytes, in both diet groups (Fig. 4.5A). The SVF was extracted 
and, following magnetic sorting, MFehi and MFelo were sorted out using macrophage 
markers by FACS. The MFelo population increased in cell count (Fig. 4.5B p<0.01). This 
response could be tied to the known obesity-associated influx of monocytes. As 
previously described by Orr et al, all recruited monocytes in obesity were MFelo, and 
there was no increase in MFehi ATMs in response to obesity71. Comparing saline to iron 
groups in both HFD and LFD, there was an upward trend in MFehi in response to iron 
injections, as had also been seen in chow iron-injection studies (Fig. 3.5A)112. Mass 
spectrometry quantification of whole tissue showed that, in obesity, total ATMs only had 
1/3 as much iron per cell in response to the iron injection (Fig. 4.5C, p<0.0001). The 
change in macrophage iron was parsed out by sorting MFehi and MFelo. Unexpectedly, 
MFehi from obese AT appeared to take up the same amount of intracellular iron in HFD 
as in LFD mice (Fig. 4.5 D, p<0.0001). This effect was further confirmed by calculating 
the total iron in all MFehi and MFelo, multiplying total cells by iron content per cell. Again, 
there was no change in the total MFehi iron pool (Fig. 4.5E). While there was an 
increase in iron in the MFelo ATM pool in HFD mice, this increase was driven only by 
increased cell counts (Fig. 4.5E, p<0.0001).   
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Figure 4.4. Body weight of C57BL/6J mice over 16 weeks of diet. At 1 week prior to sacrifice, 
weight-matched groups were separated for iron injection sub-groups. Significant differences were 
identified using ANOVA and t-test, with the following p-value indicator: ****p<0.0001. 
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Figure 4.5. Effect of obesity on iron uptake by ATMs. C57BL/6J mice on 16 weeks of LFD or HFD 
were given a IP injection of 5mg/kg iron-100 1 week prior to sacrifice. (A) Whole AT was fixed and 
sectioned, then stained with Prussian blue to visualize iron and counter-stained with nuclear red. Cells 
were sorted in order to quantify (B) ATMs per gram of tissue (N=3-5),  (C) iron content per ATM (N=4-5), 
and (D) iron content in MFelo and MFehi (N=3-5). (E) Total population iron was calculated by multiplying 
the iron/cell in each cell type by the total cell counts. For all studies, significant differences were identified 
using ANOVA and t-test, with the following p-value indicators: **p<0.01, ***p<0.001 ***p<0.0001. 
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Obesity ameliorates the MFehi genetic response to iron uptake 
 Macrophages respond to altered iron availability through IRPs that directly impact 
transcription of iron-related genes. Therefore, gene expression of iron-related genes is 
one way to investigate a macrophage’s iron state. Sorted MFehi and MFelo were 
collected to determine their response to iron injections, specifically to compare LFD and 
HFD. As in the previous study, there were 4 study groups: LFD with saline or iron 
injection, and HFD with saline or iron injection. The observed increases in iron-
associated gene expression comparing MFehi to MFelo in saline groups were 
reminiscent of the iron-cycling phenotype, as previously described71 (Fig. 4.6A - F) 
MFehi from LFD-fed mice also responded to iron injections just like MFehi from chow 
mice; there was a significant decrease in expression of Tfrc and increased expression 
of Hmox, Fth1, Ftl1, and Slc40a1 (Fig. 3.6, Fig. 4.6A - F). Of particular interest to this 
study, when comparing these same iron-handling genes in the HFD mice, all significant 
differences were lost (Fig. 4.6A - F). Lastly, while MFehi had higher levels of Spic in 
control groups, this difference was lost following both iron injection and HFD treatments 
(Fig. 4.6G).  
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Fig. 4.6 Effect of iron injection on ATM expression of iron-handling genes. C57BL/6J mice on 16 
weeks of LFD or HFD were given a IP injection of 5mg/kg iron-100 1 week prior to sacrifice. Iron-handling 
genes were quantified by RT-PCR for MFelo and MFehi ATMs (N=5). For all studies, significant differences 
were identified using ANOVA and t-test, with the following p-value indicators: *p<0.05, **p<0.01, 
***p<0.001, ***p<0.0001. 
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Polarization, oxidative stress, and arginase metabolism responses to iron 
injection and HFD 
 Baseline differences in the M1-marker Itgax (CD11c) and M2-marker Retnla were 
observed between MFelo and MFehi in lean mice (Fig. 4.7A & B), in agreement with 
previously described polarization differences between the cell types (Fig. 1.3C). In 
response to HFD, Itgax transcript levels increased in all groups, and Retnla decreased 
(Fig. 4.7A & B). This inflammatory response to HFD was not unexpected, and reflects 
the M1-skewing of MFehi in obesity, as well as the influx of M1 ATMs to the MFelo 
population in obesity71. In these studies, there was no M2-skewing of MFehi, previously 
observed as a response to iron injection (Fig. 3.8C - E). HFD nearly ameliorated 
significant differences in polarization between MFehi and MFelo.  
 Nrf2 (Nfe2l2) is a master regulator of the antioxidant response, and it is rendered 
nonfunctional by Keap1 (Keap1). In ATMs, we observed an increase in Nfe2l2 and 
Keap1 in MFehi compared to MFelo, although these differences were lost on HFD (Fig. 
4.7C & D). In general, HFD lead to an upward trend in Nfe2l2, and a significant 
reduction in Keap1 in all groups (Fig. 4.7C & D). Excess iron did not appear to impact 
either gene (Fig. 4.7C & D).   
 Upregulation of arginase (Arg1) is linked to M2-polarization and reduced 
production of ROS (Fig. 4.3A). There were no significant differences in the gene 
expression for the arginase-uptake protein, Slc7a2 (CAT2), except in MFelo with HFD 
(Fig. 4.7E). Even though MFehi are more M2-polarized, in lean mice, Arg1 was 
decreased in MFehi relative to MFelo (Fig. 4.7F)  This difference was lost in HFD, as 
MFelo reduced their expression of Arg1. iNOS (Nos2) is the enzymatic competitor to 
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arginase in arginine catabolism. In lean mice, Nos2 was upregulated in MFehi relative to 
MFelo (Fig. 4.7G). While this is unexpected considering strong M2-polarization of MFehi, 
it corresponds with reduced Arg1 expression in this cell. However, with iron injections, 
MFehi demonstrated both low Arg1 and Nos2, while maintaining Slc7a2. This occurred 
in MFehi of both saline and iron-injected mice on HFD. 
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Figure 4.7. Effect of iron injection on ATM polarization and inflammation genes. C57BL/6J mice on 
16 weeks of LFD or HFD were given a IP injection of 5mg/kg iron-100 1 week prior to sacrifice. Iron-
handling genes were quantified by RT-PCR for MFelo and MFehi ATMs (N=5). Genes of interest can be 
grouped into (A,B) Polarization-associated genes, (C,D) antioxidant-pathway regulatory genes, and (E-G) 
arginase catabolism pathway genes. For all studies, significant differences were identified using ANOVA 
and t-test, with the following p-value indicators: *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001. 
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Adipocyte response to iron injection in HFD 
 Previous studies demonstrated that in obesity MFehi had decreased iron content 
and adipocytes had a four-fold increase in iron (Fig. 4.2A). However, in these studies, 
we observed no significant changes in iron content in adipocytes in obese mice (Fig. 
4.8A). Furthermore, we observed an increase in iron content in the liver in response to 
iron injections in LFD, but no difference in iron content between LFD and HFD (Fig. 
4.8B).  
 Looking at adipocyte gene expression, there was no response in Tfrc in HFD, or 
iron injections (Fig. 4.9A). This correlates with unaltered cellular iron content (Fig. 4.9A). 
However, there was a significant increase in Hmox1 in HFD (Fig. 4.9B), a previously 
described trend (Fig. 4.2C). Unchanged Ftl1 and decreased Fth1 (Fig. 4.9C & D) also 
contradicted the very significant increase in Fth1 and Ftl1 observed in previous studies 
in HFD (Fig. 4.2C). Again, these findings would correspond with low adipocyte iron 
storage. The other very significant responses seen in these studies were in Slc40a1, the 
iron-exporter Fpn (Fig. 4.9E), contrasting the downward trend previously described (Fig. 
4.2C). While Tnfa and Adipoq responded to the HFD stimulus as would be expected in 
obese mice, their expression was not impacted by excess iron (Fig. 4.9G & H).  
 In general, these adipocyte results did not align with the premise of our studies 
and spurred further inquiry into adipocyte and liver iron content over the course of HFD 
studies. These studies are detailed in the next sections. 
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Figure 4.8. Tissue iron content after iron injections in HFD-fed obesity model. C57BL/6J mice on 16 
weeks of LFD or HFD were given a IP injection of 5mg/kg iron-100 1 week prior to sacrifice. Tissue iron 
content was quantified by atomic absorption spectrometry in (A) adipocytes, standardized to protein 
concentration, and (B) liver, standardized to tissue weight. For all studies, significant differences were 
identified using ANOVA and t-test, with the following p-value indicator:  ***p<0.001 
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Figure 4.9. Effect of iron injection on adipocyte gene expression. C57BL/6J mice on 16 weeks of 
LFD or HFD were given a IP injection of 5mg/kg iron-100 1 week prior to sacrifice. Iron-handling genes 
were quantified by RT-PCR for adipocytes (N=5). Genes of interest can be grouped into (A-E) Iron-
associated genes, (F,G) inflammatory cytokines, and (H) the adipokine, adiponectin. For all studies, 
significant differences were identified using ANOVA and t-test, with the following p-value indicators: 
*p<0.05, **p<0.01, ***p<0.001, ***p<0.0001. 
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Liver lipids and iron in a HFD feeding time course 
 C57BL/6J mice were on HFD for 14, 16, 18, or 20 weeks. There was no 
significant difference in liver weight between these time points (Fig. 4.10A). 
Furthermore, liver fat accumulation was not significantly changed, whether it was 
quantified by live-animal hydrogen MR spectroscopy (Fig. 4.10B) or by post-mortem 
liver TG assay (Fig. 4.10C). While there was an upward trend in liver iron, there were no 
significant differences between the 14-20 week time points (Fig. 4.10D). When all data 
points were combined, no significant correlation was found between liver TG and liver 
iron content (Fig. 4.10E). 
 
AT lipids and iron in a HFD feeding time course 
 AT results were similar to liver results; no significant differences were seen in AT 
weight relative to body weight from 14 to 20 weeks of HFD (Fig. 4.11A). Specifically, we 
did no observe a drop in eAT fat pad weight at 16 weeks, a critical time point for AT 
remodeling, as reported by Strissel et al. (Fig. 4.1)28. While there was an upward trend 
in adipocyte iron at 20 weeks, there were no significant changes over the time course 
(Fig. 4.11B). The only linear correlation observed in these studies occurred between 
liver iron and adipocyte iron, likely reflecting systemic iron stores (Fig. 4.11C). When the 
data points were separated out by time point, the correlation between liver and 
adipocyte iron had a non-significant slope from zero (data not shown).  
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Figure 4.10. Liver iron and lipid accumulation over 14- to 16-weeks of HFD. C57BL/6J mice were 
sacrifice at either 14, 16, 18, or 20 weeks of HFD. (A) Total liver weight was collected at sacrifice. (B) 
Liver fat accumulation in vivo was quantified by hydrogen MS spectroscopy. (C) Liver TG were quantified 
by a colorimetric assay. (D) Liver iron was quantified by atomic absorption spectrometry. (E) Linear 
correlation between liver iron and liver TG with a non-significant slope from zero. For all studies, 
significant differences were identified using ANOVA and t-test. 
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Figure 4.11. Adipocyte weight and iron over 14- to 16-weeks of HFD. C57BL/6J mice were sacrifice at 
either 14, 16, 18, or 20 weeks of HFD. (A) Total epididymal fat pad weight was collected at sacrifice. (B) 
eAT weight relative to subcutaneous (subQ) fat pad weight, (C) Adipocyte iron quantified by atomic 
absorption spectrometry. (D) Linear correlation between liver iron and adipocyte iron with a significantly 
non-zero slope (p=0.03). For all studies, significant differences were identified using ANOVA and t-test, 
with the following p-value indicators: **p<0.01. 
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Discussion 
 We initially hypothesized that MFehi would have attenuated iron-uptake in obese 
AT. This hypothesis was based on the observation that MFehi have decrease 
intracellular iron in obesity, and adipocytes have a four-fold increase in iron content. 
Furthermore, in lean AT, MFehi have strong M2-polarization and high expression of all 
iron-handling genes. In obesity, both M2-polarization genes and iron-uptake/iron-
release genes were reduced. The studies outlined in this chapter combined the high 
iron model from Chapter III with a HFD-induced obesity model in order to “test” MFehi 
iron-handling in obesity.  Surprisingly, we found that MFehi were still able to take up iron 
in HFD. However, their iron-handling phenotype was blunted in obesity, even with 
excess iron uptake. Their inflammatory polarization may alter their ability to be as 
flexible in their iron-handling genes. This presents an interesting follow up question: 
does altered flexibility in iron handling by MFehi in obesity impact their ability to provide 
iron for adipogenesis during AT remodeling?  
 Previous studies from our lab had shown that obesity is associated with a four-
fold increase in adipocyte iron content (Fig. 4.2A)71. However, in these studies we did 
not observe this increase in adipocyte iron, nor the decrease in liver iron, at 16 weeks of 
HFD. Studies by other laboratories have demonstrated that 16 weeks of HFD in 
C57BL/6J mice is a critical time point of tissue remodeling. We considered that the 
contradictory findings between our studies and those of earlier work in our laboratory 
may have occurred due to differences in timing around this tissue remodeling. 
Therefore, we designed a study to correlate eAT and liver iron with lipid handling, and a 
way to assess this inflection point in vivo prior to mouse sacrifice. We used hydrogen 
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MS spectroscopy to quantify liver lipid content, as well liver TG content post-mortem. 
However, no differences were observed over the 14- to 20-week time course. 
Furthermore, we saw no differences in eAT weight or adipocyte iron content. While 
these negative findings are useful, they were unable to explain the contradictory 
findings in adipocyte and liver iron between the studies describe herein and those 
published by Orr et al. Future studies may benefit from adipocyte iron quantitation by 
ICP-MS, as well as sample standardization by metals, such as sulfur, rather than tissue 
weight. 
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CHAPTER V  
 
TARGETING MFehi ATMS IN VIVO 
 
Introduction 
Potential methods for targeting cells  
 
 The studies outlined in previous chapters suggest that MFehi have an iron-
handling role in AT. However, in order to mechanistically address the necessity of MFehi 
and their role in tissue homeostasis, our lab sought to target MFehi ATMs for depletion 
or functional alteration. Some common methods for cell targeting include: germline 
knockout of a developmentally-required gene specific to the cell type, conditional 
knockout of a gene specific to the cell type (i.e. with the Cre-Lox system), and 
nanoparticle delivery of toxins or siRNA targeted to that cell. 
 Germline knockout: Developmental knockout of macrophages has been 
accomplished. Examples include the op/op mouse, which is deficient in colony 
stimulating factor-1139.  However, op/op mice have extensive developmental 
malformations. For this reason, developmental macrophage knockdown methods are 
primarily useful to address hypotheses concerning the developmental role of 
macrophages, not the functional role of macrophages in normal tissues. These 
malformations could possibly be avoided by knocking down a less generic macrophage 
gene, but no genes required specifically for the development of MFehi ATMs have been 
found. However, we have described elevated SpiC in MFehi ATMs (Fig. 3.3J & 4.6J). 
However, SpiC shares the same limitations as other developmental genes: it would not 
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target the knockdown to macrophages only in AT, and would include splenic red pulp 
macrophages.  
 Conditional knockout: In order to avoid developmental defects, conditional 
macrophage knockouts has been achieved with the Cre-Lox system under control of 
macrophage-specific gene expression. For example, mice with a lysozyme M (LysM) 
promoter-driven Cre with an excisable STOP codon in the diphtheria toxin receptor can 
be given diphtheria to induce a temporary knockout of LysM140. However, macrophages 
are known for the wide range of functions they play in nearly all tissues, and this type of 
global macrophage knockout study is confounded by the dysfunction of tissues in the 
whole organism. In our case, we are interested in understanding the specific function of 
one type of macrophage - and only in AT.  
 Liposomes and nanoparticles: The limitations of genetic knockdowns outlined so 
far have motivated investigators to develop small particles that can target macrophages 
especially well because they are both highly phagocytic and endocytic. The ideal design 
is a small particle that is taken up into the tissue of interest and can target a type of cell 
identifiable through a cell-surface protein. Ideally, such small particles would carry 
cytotoxins for cell depletion, or siRNA to alter the cell’s function. A secondary benefit of 
a well-designed small particle method is the potential for translation into medical 
applications in humans. Currently, small particles fall into three main groups: lipid-
bilayer particles (liposomes), lipid-monolayer particles (micelles), and beta-glucan 
particles. 
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Liposome characteristics and targeting 
 Liposomes are small vesicles composed of a lipid bilayer that have a 20-year 
history of medical applications, including the delivery of nutrients or pharmaceutical 
drugs141. They are most commonly composed of phosphatidylcholine and can have 
surface alterations that allow for their targeting to specific tissues. Hydrophilic solutes 
dissolved in the core of liposomes do not diffuse across the hydrophobic lipid bilayer 
membrane. Hydrophobic substances intercalate into the hydrophobic bilayer. In either 
case, hydrophilic and hydrophobic solutes can be carried by the liposomes until the 
bilayer is disrupted – either by a detergent, fusion with a cell membrane, or by cellular 
phagocytosis.  
 Liposomes can be either multilamellar vesicles (multiple bilayers 1-5um) or 
unilamellar (single bilayer, 50-250nm); the latter is preferred for delivery of hydrophobic 
drugs because they have a large aqueous core141. Adding cholesterol to the liposomes 
stabilizes the membrane and prevents incorporation into high-density lipoprotein (HDL) 
or low-density lipoprotein (LDL)142. Liposomes can accumulate in the interstitial space in 
tumors, due to inefficient lymphatic drainage143. Thereby, they serve as a sustained 
drug-release system. In contrast, they do not exit the bloodstream where endothelial 
cells have tight junctions. Therefore, when given IV, unmodified “first-generation” 
liposomes are primarily cleared through Kupffer cell of the liver or by splenic 
macrophages144.  
 Cholesterol also allows for the attachment of PEG or other molecules to the 
surface of the liposomes to increase their blood circulation time and reduce their 
phagocytosis by the reticuloendothelial system (RES) – these are known as “second 
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generation” or “stealth” liposomes145. Specifically, PEG provides a space around the 
liposomes that buffers its interaction with other molecules (like opsonins and 
complement), and the van der Waals forces clumping liposomes together146. However, 
even with these alterations, liposomes are not inert; for example, PEGylated liposomal 
doxorubicin (DOXIL®, USA) has been shown to strongly activate the complement 
system147.  Lastly, the size of the liposome determines its uptake by the RES. 
PEGylated liposomes that have a diameter of 250nm have a circulation time that is half 
of those with 100nm diameter or less148. 
 Similar to PEGylation, liposomes can also be designed to target specific cells by 
coupling moieties to their surface to induce preferential internalization. For example, 
doxorubicin-loaded liposomes have been manipulated with surface moieties, such as 
antibodies149 and receptor ligands150, that allow for their interaction with specific cancer 
cells. An interesting area of current development in the field of targeted liposomes are 
stimuli-responsive liposomes; for example, ThermoDox® liposomes can be triggered to 
release their drug by localized heat treatment151.  
 
Liposomes for macrophage depletion 
 Cytotoxic liposomes are considered a standard method for depleting 
macrophages in vivo in rodents. Specifically, clodronate liposomes have been used by 
researchers since their development in the 1980s (ClodronateLiposome.org)152, 153.  
However, whether given IV or IP, these liposomes cannot cross vascular membranes; 
rather their uptake leads to the accumulation of clodronate in vascular macrophages, 
Kupffer cells, or splenic macrophages. At a certain threshold, clodronate induces 
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apoptosis and depletes macrophages, while released clodronate is non-toxic in low 
concentrations and simply cleared by the kidneys154.   
 For the reason described, clodronate liposomes are not a method conducive to 
selectively depleting macrophages in AT. In order to target ATMs, liposomes would 
need to be injected into the peritoneal cavity, where much of the absorption occurs 
through direct capillary absorption155. This is advantageous because eAT is an 
unencapsulated organ, in contrast to liver, kidney and spleen. Furthermore, ATM 
selectivity in lean mice would be best achieved with PEGylated liposomes with a 
surface moiety that would support selective uptake by M2-polarized macrophages. 
 While all M2-polarized macrophages are known to express the hemoglobin-
haptoglobin receptor CD163, our previous studies showed that this receptor is 
expressed higher on MFehi than MFelo 71. For these reasons, anti-CD163 liposomes 
(CD163lipos), published by the Moestrup lab (Aarhus University, Denmark), were 
methodologically promising to us. Dr. Moestrup and Dr. Etzerodt developed PEGylated 
liposomes made of hydrogenated soy L-alpha-phosphatidylcholine, cholesterol, and 
PEG at a ratio of 55:40:5 (please refer to their publication for technical biochemical 
details)110. They produced liposomes loaded with either calcein (Fig. 5.1A) or the toxin 
doxorubicin (Fig. 5.2A), and the liposomes were dialyzed to remove any extra-liposomal 
material.  
 Calcein-loaded CD163lipos (CD163lipo/calcein) allow for the visualization of 
liposome accumulation but does not interfere with normal cell function. Doxorubicin is a 
chemotherapeutic agent that increases free radical production, activates apoptosis 
pathways, and intercalates into DNA, stalling replication156. While there was no specific 
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advantage for our studies to use doxorubicin over clodronate, doxorubicin-loaded 
liposomes were readily available through the collaboration with the Moestrup lab. 
Furthermore, initial studies with non-targeted clodronate liposomes in the Hasty lab led 
to rapid and consistent morbidity (data not shown), and no adverse effects were 
observed with the CD163lipos with doxorubicin.  
 Etzerodt et al. modified CD163lipos with a rat anti-mouse antibody against 
CD163 (E10B10) or human CD163 antibody. They demonstrated that 
CD163lipos/calcein were preferentially taken up through the endocytic pathway in 
macrophages and their anti-CD163 modification increases the efficiency of uptake by 
CHO cells expressing murine CD163 in vitro nearly ten-fold110.  Furthermore, the peak 
level of uptake occurred at 32 hours after exposure, but was maintained up to their last 
time point, at 48 hours. In vivo experiments were performed in BALB/c mice IP injected 
with 200ul of 0.67mM liposome solutions and demonstrated increased uptake of 
CD163lipos/calcein over untargeted calcein-loaded liposomes by 30 min. When human 
monocytes were incubated with untargeted dox liposomes (lipo/dox, Doxil®) versus 
CD163lipos/dox, viability decreased from 96% to 53%. This is because the targeted 
delivery of dox through the CD163lipos allowed for sufficient dox accumulation 
intracellularly to induce apoptosis.  
 Ultimately, the advantages of targeted stealth liposomes outlined in this section, 
and the previous utility of CD163lipos by Etzerodt et al. lead to the application of 
CD163lipos as a tool to target MFehi in this chapter. 
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Micelle nanoparticles 
 Micelles are simply an aggregation of amphoteric lipids. In aqueous solutions, 
they can spontaneously form spheres with hydrophilic head groups outward, and lipid 
tails inward. They are detergents because they can carry insoluble materials within their 
hydrophilic center. Micelles caught the attention of researchers and the pharmaceutical 
industry because they are also able to “carry” siRNA through an aqueous environment, 
like blood, protected from degradation by RNAses. Like liposomes, combining micelles’ 
siRNA carrying capacity with targeting moieties could be a powerful way of delivering 
siRNA in vivo to a subtype of cells.  
 Functional delivery of siRNA to a specific cell require that: (1) the carrier has a 
cell targeting moiety, (2) siRNAs are protected from RNAses in transit, and (3) the 
siRNAs are delivered in a way that maintains their capacity to bind mRNA in the 
cytoplasm, inhibiting translation of the target gene. In 2013, the Giorgio lab (Vanderbilt 
University, USA) developed tri-block mannosylated polymer nanoparticles (MnNPs) that 
fulfill the specifications listed above in the following ways111: (1) These MnNPs use 
copper (I) “click” chemistry to attach mannose to the polymer surface, thereby targeting 
cells with high expression of the mannose-receptor CD206; (2) MnNPs have a 
poly(DMAEMA) polymer with a polycationic charge that can condense siRNA, protecting 
it from degradation; (3) MnNPs have a very unique hydrophobic, pH responsive core 
that allows the siRNA to escape endosomal degradation to reach the cytoplasm (Fig. 
5.6A). 
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 MnNPs have been used in vivo to target CD206hi TAMs111. Mannosylation of the 
NPs increased delivery to primary macrophages 4-fold, and achieved 87% knockdown 
of their gene of interest. MnNPs also delivered 13-fold more siRNA to TAMs than 
cancer cells. Repeated treatment with MnNPs in vivo did not lead to liver or kidney 
dysfunction in mice, but delivered siRNA to mammary tumors and lung metasteses157.  
 Modulating specific signaling pathways is a more refined method of delineating 
the function of a cell in a system – rather than just eliminating the cell entirely. 
Therefore, siRNA technology opens up many more options for characterizing the 
importance of M2-like cells, like MFehi in the context of iron-handling. Using Dr. 
Giorgio’s MnNPs could allow for the delivery of siRNA of interest to CD206hi ATMs, like 
MFehi, in a way that avoids the endosomal degradation pathway. This chapter includes 
preliminary studies concerning MnNP targeting for use in vivo in the context of AT. 
  
Beta-glucan nanoparticles 
 Beta-glucan particles are polymeric carbohydrates sourced from microbes that 
have also been used to target macrophages specifically. Due to their source, these 
nanoparticles are recognized by the pathogen-recognizing dectin-1 receptor on 
macrophages. Beta-glucan particles have been formulated to carry drugs to 
macrophages for tuberculosis therapy158, and to carry siRNA to silence inflammatory 
genes in macrophages, reducing obesity-associated glucose intolerance159. Because 
beta-glucan nanoparticles are intended to target M1-polarized macrophages, they were 
not used in these studies but were included here for a complete representation of the 
breadth of methods available for targeting macrophages. 
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Results 
Calcein-loaded CD163 liposome injections  
 CD163lipo studies were initiated using CD163lipo/calcein injections in order to 
quantify their relative uptake by MFelo and MFehi ATMs, and to grossly assess the 
uptake of these liposomes into specific peritoneal tissues. Mice were injected with 
saline, 0.1mM CD163lipo/calcein, or 1.0mM CD163lipo/calcein. 24 hours later, ATMs 
were magnetically sorted and analyzed by flow cytometry. Results indicated that they 
were taken up by both MFehi and MFelo, with preferential uptake by MFehi in the lower 
dose, but a consistent high uptake of 80% in the high dose in both cell types (Fig. 5.1B). 
Based on these results, all further CD163lipo injections were performed at an 
intermediate concentration of 0.67mM lipid. In another experiment, whole tissues were 
collected for fluorescent imaging. After background fluorescence was subtracted, it was 
visually apparent that calcein fluorescence was only present in the various peritoneal 
AT samples – not in liver, kidney, spleen, or lung (Fig. 5.1C).  
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Figure 5.1. Quantifying targeting of CD163lipos to ATMs using a fluorescent marker. (A) A 
schematic of PEG-coated lipid bilayer liposomes coated with anti-CD163 antibody and loaded with calcein 
that were used to assess the targeting of CD163hi macrophage. (B) Calcein fluorescence in ATMs from 
mice injected with either PBS, low-dose CD163lipo/calcein, or high-dose CD163lipo/calcein. (C) Whole-
tissue imaging for calcein fluorescence from mice injected with 0.03uM of CD163lipo/calcein. Results 
visually demonstrate preferential uptake by AT following IP injection of CD163lipo/calcein, rather than 
liver, lung, spleen or kidney. Significant differences were identified using ANOVA and t-test, with the 
following p-value indicators: **p<0.01. 
	   100	  
CD163 liposome-mediated ATM depletion with iron injections 
 The goal of this study was to understand how adipocytes respond to excess iron 
when MFehi ATMs have been depleted. In order to address this question, 
CD163lipo/empty and CD163lipo/dox study groups were combined with saline and iron 
injections in a 2 x 2 study design. Preliminary studies were performed to assess the 
efficacy of CD163lipo/dox-mediated depletion. Supporting our ability to target CD163hi 
cells, whole eAT gene expression of Cd163 was reduced in both groups receiving 
CD163lipo/dox compared to CD163lipo/empty controls (Fig. 5.2B) Reflecting the 
preferential uptake into AT we noted in our calcein studies, Cd163 expression was not 
reduced in the liver (Fig. 5.2C). Similarly, by flow cytometry, there was significant 
reduction in CD163+ ATMs in the eAT samples from mice with cytotoxic liposomes, 
which was not seen in liver (Fig. 5.2D). In a replicate experiment, the ATMs were 
magnetically sorted prior to flow cytometry. As previously described, iron injection was 
associated with a significant increase in the count of MFehi but not MFelo (Fig. 5.2E). 
Superimposed on this iron-injection effect, there was a significant reduction in the count 
of MFehi in mice that received cytotoxic CD163lipos (Fig. 5.2E). 
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Figure 5.2. Targeted uptake of CD163lipos by ATMs. (A) A schematic of PEG-coated lipid bilayer 
liposomes coated with anti-CD163 antibody and loaded with the cytotoxin doxorubicin (CD163lipo/dox) to 
deplete CD163hi ATMs. (B) Epididymal AT and (C) liver expression of Cd163 demonstrates knockdown in 
only the eAT. (D) Flow cytometry of macrophages in eAT and liver demonstrate a significant reduction in 
CD163+ ATMs. (E) Magnetically-sorted ATMs demonstrate a preferential reduction in MFehi, not MFelo, 
with cytotoxic CD163lipos. For all studies, significant differences were identified using ANOVA and t-test, 
with the following p-value indicators: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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 AT response to iron-injections with MFehi depletion 
 
 After we had established that MFehi were depleted in the CD163lipo/dox study 
with iron-injection, insulin action in AT was assessed by Western-blot quantification of 
pAkt. Specifically, each study group was divided to receive either PBS or insulin 
injection 15 minutes prior to sacrifice. Tissue was collected and assessed for expression 
of pAkt relative to total Akt in eAT, liver and muscle. In eAT, there was the expected 
increase in pAkt/Akt in response to insulin injection (Fig. 5.3A & B). However, in the 
group that had ATM depletion and iron-injections, this increase in pAkt/Akt was lost (Fig. 
5.3A & B). In contrast, in liver and muscle, the fold-increase in pAkt in insulin-injected 
mice was robustly present in all study groups (Fig. 5.3A, C & D).  
 Based on previous studies, we expected that adipocytes would have no 
difference in iron content in response to iron injections (Fig. 3.5D). Furthermore, in this 
study specifically, we expected an increase in adipocyte iron content only with ATM 
depletion and high iron. However, AAS iron quantification showed an increase in 
adipocyte iron in all iron injection groups (Fig. 5.4A). Furthermore, this effect was 
actually blunted in mice with ATM depletion (Fig. 5.4A). Adipocytes also had an 
increase in the expression of Tnfα in both saline and iron CD163lipo/dox groups (Fig. 
5.4B), and an increase in Il1β in the CD163lipo/dox iron group (Fig. 5.4C). However, 
there was no significant change in Adipoq between groups (Fig. 5.4D). Similarly, there 
were no significant differences in plasma adiponectin between the groups (Fig. 5.4E). In 
general, CD163lipo/dox lead to increased serum Tf (Fig. 5.4F), and iron injections and 
CD163lipo/dox had an additive effect in increasing serum Ft (Fig. 5.4G).  
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Figure 5.3. Insulin signaling following CD163hi ATM depletion and iron injection. Experimental 
groups (CD163lipo/dox with saline or iron) and control groups (CD163lipo/empty with saline or iron) were 
injected with either saline or insulin. (A) The insulin signaling response was quantified by Western blot of 
pAkt and Akt. From these blots, the relative ratio of pAkt/Akt was calculated in (B) adipose tissue, (C) 
liver, and (D) muscle. Significant differences were identified using ANOVA and t-test, with the following p-
value indicators: *p<0.05, **p<0.01, ****p<0.0001. 
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Figure 5.4. AT and plasma parameters after CD163hi ATM depletion and iron injection. (A) Iron was 
quantified by AAS in the adipocyte fraction. Gene expression in whole AT was assessed for (B) Tnfα, (C) 
Il1β, and (D) Adipoq. Plasma was collected to quantify (E) plasma adiponectin, (F) total iron binding 
capacity, (G) serum transferrin, and (H) serum ferritin. For all studies, significant differences were 
identified using ANOVA and t-test, with the following p-value indicators: *p<0.05, **p<0.01. 
	   105	  
Adipose tissue treated ex vivo with cytotoxic liposomes 
 To circumvent possible off-targets effects from exposing the whole peritoneum to 
CD163lipos, we also treated eAT fat pads with CD163lipo/dox ex vivo. First, the ex vivo 
model had to be established; fat pads were collected at different time points in order to 
assess their physiological state in culture over 48 hours. RT-PCR analysis on whole fat 
pads that had been ex vivo demonstrated a drop in Adipoq starting at the first time 
point, and maintained for 48 hours (Fig. 5.5A). While there was an initial increase in the 
inflammatory gene Tnfa at 12 hours, this returned to normal after 24 hours (Fig. 5.5B). 
However, Nos2 expression was increased at 48 hours (Fig. 5.5C); possibly indicating 
that explants undergo oxidative stress when they have been 48 hours in culture. Lastly, 
we demonstrated that Xiap, a inhibitor of apoptosis, was down-regulated starting at 12 
hours (Fig. 5.5D). When we assessed for macrophage knockdown in these explants by 
flow cytometry, there were no significant differences in MFelo, and only a small reduction 
in MFehi at 1.27mM dose of doxorubicin for 24 hours. However, at 48 hours there was a 
downward trend in MFehi which did no occur in MFelo. While this further supports the 
specificity of CD163lipo targeting to MFehi with high expression of CD163, the trends in 
Adipoq, Nos2, and Xiap suggested that this ex vivo methodology was too confounded 
by physiologic dysfunction of the eAT for further applications.  
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Figure 5.5. CD163lipo treatments in AT explants. The physiologic health of AT explants was analyzed 
over 0-48 hours by quantification of certain genes, including(A) Iron was quantified by AAS in the 
adipocyte fraction. Gene expression in whole AT was assessed for (B) Tnfα, (C) Il1β, and (D) Adipoq. 
Plasma was collected to quantify (E) plasma adiponectin, (F) total iron binding capacity, (G) serum 
transferrin, and (H) serum ferritin. For all studies, significant differences were identified using ANOVA and 
t-test, with the following p-value indicators: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Mannosylated nanoparticle delivery of siRNA 
 MnNPs allow for the delivery of siRNA, with the intention of altering a specific 
cell’s physiology. In these studies, MnNPs were loaded with different combinations of 
three siRNA molecules against the iron-exporter Slc40a1 (Fpn) and used for in vitro 
treatments of M2- and Mme-polarized bone marrow-derived macrophages (BMDMs). 
These MnNPs were expected to preferentially target cells with high expression of the 
mannose receptor, CD206. In preliminary studies with BMDMs, we observed a 50% 
knockdown of Slc40a1 in M2-polarized BMDMs using the “B” combination of three 
siRNAs (Fig. 5.6B). There was no significant reduction in Slc40a1 with any treatments in 
Mme-polarized BMDMs (Fig. 5.6B). We intended to apply this combination of siRNAs 
for in vivo injections. However, due to the cost associated with high doses of siRNA 
required for in vivo experiments, we chose to secondarily verify the preferential uptake 
of MnNPs by CD206hi ATMs. For this purpose, MnNPs loaded with fluorescent Cy5+ 
double-stranded DNA (Cy5+dsDNA) were incubated with polarized BMDMs. After 48 
hours, BMDMs were assessed by flow cytometry using macrophage markers (F4/80 
and CD11b), as well as CD206. Saline was used as a control for autofluorescence, and 
free Cy5+dsDNA served as a control to assess for nonspecific uptake of the dsDNA. As 
would be expected by our polarization stimulus, M2-polarized BMDMs had a two-fold 
increase in CD206, while Mme- and M1-polarized BMDMs had reduced CD206 (Fig. 
5.6C). When we assessed Cy5+ fluorescence, comparing the negative control (NC) to 
either Cy5+dsDNA treatment or Cy5+dsDNA MnNPs, it was clear that the Cy5+ signal 
was a true signal, not background autofluorescence. However, in these differentially 
polarized BMDMs, there was no preferential delivery of Cy5+ dsDNA to M2-polarized 
	   108	  
CD206hi BMDMs (Fig. 5.6D). In fact, unpolarized and M1-polarized BMDMs had the 
highest levels of fluorescence associated with MnNP uptake.  Furthermore, this uptake 
of Cy5+dsDNA occurred even in the absence of MnNP (Fig. 5.6D). These findings 
suggest to us that the MnNPs at this stage in development did not provide an efficient 
method of delivering siRNA to M2-polarized macrophages.  
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Figure 5.6. Testing mannosylated nanoparticle specificity. (A) A model of mannosylated nanoparticle 
(MnNP) delivery of siRNA to macrophages. (B) Preliminary testing of different iterations of three siRNA 
combinations loaded onto MnNPs and provided to either M2- or Mme-polarized bone marrow derived 
macrophages (BMDMs). (C) CD206 expression was quantified by flow cytometry in BMDMs of different 
polarization statuses. (D) Polarized BMDMs were treated with a negative control (NC), free Cy5-
conjugated dsDNA (Cy5dsDNA), or Cy5dsDNA loaded onto MnNPs. Cy5 fluorescence was quantified in 
cells positive for F4/80 and CD11b. For all studies, significant differences were identified using ANOVA 
and t-test, with the following p-value indicator: *p<0.05. 
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Discussion 
 The ubiquitous presence of macrophages in most tissues of the body makes 
them difficult to target with specificity. Simultaneously, the unique adaptations and role 
macrophages play in resident tissues makes them appealing to study in a targeted way. 
The field of immunometabolism has been seeking a way to target ATMs, and other 
tissue-associated macrophages, in order to understand the implications they have for 
whole-body physiology.  
 This chapter gives insight into preliminary studies, attempts, and limitations of 
two methods of targeting ATMs. In this case, targeting of MFehi instigated both of the 
collaborations that lead to our use of CD163lipos and MnNPs. In the studies with 
CD163lipo/calcein in vivo, it was apparent that these liposomes were taken up primarily 
into the AT of the peritoneal cavity, rather than other organs. Not only does the PEG 
coating of the CD163lipos support their ingestion by macrophages, but it is possible that 
the organ capsules on liver, spleen, and kidney prevent their ready uptake. The 
preferential uptake of CD163lipos into AT was also reflected in reduced expression of 
Cd163 in AT relative to liver, following the injection of cytotoxic CD163lipos. 
Furthermore, sorting MFehi and MFelo following CD163lipo injection show that their 
uptake could be somewhat targeted toward the MFehi - “CD163hi” - ATMs with the 
correct dosage. These were all encouraging results and bode well for future studies 
using CD163lipos to target CD163hi macrophages in AT. 
 The intent of using CD163lipos was to determine if CD163hi ATMs were 
necessary for iron homeostasis in AT. To this end, CD163lipo ATM depletion was 
combined with iron injections. The results of these studies opened up more questions; 
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we were especially intrigued if these results may indicate that the empty CD163lipos 
could induce adipocyte iron uptake. To address this finding, we would need to use a 
non-liposome (saline) control group in future studies. Lastly, iron quantification in 
adipocytes in these studies could be performed with ICP-MS and AAS to verify that the 
quantification was consistent. However, the targeted uptake of CD163lipo that was seen 
in these studies suggests that this methodology could still prove to be useful in 
addressing these or other questions.  
 Preliminary studies were performed with CD163lipos ex vivo in order to avoid off-
target effects and narrow in on eAT physiology. However, analysis of AT explants from 
these studies suggested that the explant methodology itself was confounded by the 
health of the tissue. Once it was identified that CD163lipos are preferentially taken up 
into AT in vivo, explants studies were not further pursued.  
 MnNPs were assessed as a method of altering the function of macrophages 
using siRNA against specific genes. In this context, the intention was to knock down 
either iron-uptake or iron-release genes in ATMs to assess the role of ATMs in iron 
handling and their impact on adipocyte or AT health. The studies outlined in this chapter 
were preliminary studies to confirm that mannosylation of the NPs did actually lead to 
preferential uptake by cells with high expression of CD206 – a protein highly expressed 
on M2-like macrophages, including MFehi. While we were able to induce a 50% 
knockdown of Slc40a1, further studies using a fluorescent marker dsDNA did not 
demonstrate the preferential uptake by CD206hi macrophages that had previously been 
described157.  What was particularly concerning to us was that uptake was enhanced in 
M1-polarized macrophages in this system, and that uptake occurred whether the 
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dsDNA was provided with or without the MnNPs. After discussing these findings with 
the collaborating lab (Dr. Giorgio, Vanderbilt), it was decided to not pursue this 
technology for in vivo applications until modifications had been made to the MnNPs.  
 While the field of immunometabolism commonly focuses on the influx of 
monocyte-derived inflammatory macrophages in obesity, it is also commonly accepted 
that resident M2-polarized ATMs play a role in maintaining homeostasis of lean AT. 
However, studies of resident ATMs have been limited by our inability to target them. It 
has not been possible to demonstrate that they are, by definition, “necessary”, and to tie 
their presence to a specific type of physiological homeostasis. The two technologies 
outlined in this chapter – CD163lipos and MnNPs – were pursued for exactly this 
reason. While the CD163lipo/iron studies had unexpected results, and the MnNPs we 
used need to be further optimized, both of these methods have unique qualities that 
demonstrate great potential for future applications.  
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CHAPTER VI  
 
SUMMARY AND CONCLUSIONS 
 
 
 Immunometabolism is a field that was born from the discovery of immune cells in 
metabolic tissues, such as AT26. In fact, the field is part of a broader scientific 
understanding that dysregulation of the immune system may underlie many of the 
modern, chronic “uncured” diseases – such as vascular hypertension, pulmonary 
hypertension, non-alcoholic steatohepatitis, cancer, autoimmune diseases, and type 2 
diabetes160-164.  
 Immune cells evolved to contend with infectious microbes by functioning as a 
system with flexibility and complexity from both cellular diversity and intricate 
intercellular interactions. This also gives the immune system the ability for acute 
accommodation and chronic adaptation to environmental cues, spatially and temporally. 
It can be surmised that these qualities explain why immune cells have been 
evolutionarily coopted to respond to environmental cues and maintain other types of 
homeostasis – such as metabolism.  
 Classic metabolism-associated cells – like hepatocytes, beta cells, muscle cells, 
and adipocytes – are very specialized, making them sensitive to perturbation. This has 
limited the successful medical therapies available to treat metabolic dysfunction of these 
cell types, leaving some metabolic diseases “incurable”. For this reason, there is a 
growing appreciation for therapies that target the immune cells in the tissues instead165.  
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As the technology to modulate tissue-associated immune cells progresses rapidly, so 
must our understanding of the natural function of these cells.  
  Immune cells use nutrient partitioning as a way to limit the growth of invasive 
microbes166, 167. For example, monocytes have developed methods to sequester metals 
in plasma during an infection, while microbes respond with complex ways to steal away 
these same metals. A very similar interaction plays out between cancerous cells and 
TAMs168. These examples highlight the importance of metals to all living cells. As 
discussed in the Introduction, fine-tuned metal availability is likewise important in the 
function of metabolic cells, like adipocytes17. For this reason, it was fortuitous, but not 
altogether surprising, when our lab discovered that macrophages are involved in iron-
handling in AT71.  
 DIOS – or dysmetabolic iron overload syndrome – is a syndrome that describes 
aberrant iron storage in certain cell types in association with the metabolic syndrome169.  
This syndrome was based on a growing set of human and rodent studies that correlate 
systemic iron stores and metabolic dysfunction, independent of inflammation51, 54, 56, 170-
172.  Further studies have shown that many cells aside from macrophages require iron to 
function and replicate, but they can be sensitive to oxidative stress from excess iron. 
This supported the findings by our laboratory that MFehi may be responsible for iron-
handling in adipose tissue. While the previous studies by Orr et al. described the 
phenotype of MFehi ATMs in lean and obese AT, and proposed interesting hypotheses, 
no functional studies were performed to ascertain their iron-handling capacity. The 
experiments described in Chapters II-V of this dissertation were designed to probe the 
function and necessity of ATMs for iron homeostasis in lean and obese AT (Fig. 5.7). 
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 In Chapter III, iron-diet and iron-injection were introduced as two models of iron 
excess in the mouse. The advantage of the iron-diet model was its chronicity and 
physiologic relevance. The iron-injection model offered a more acute and direct 
approach to providing excess iron in AT. Both studies demonstrated gene-level 
responses to excess iron only in MFehi, not MFelo. In addition, changes in the count of 
MFehi were attributed primarily to MFelo “conversion” to MFehi. This finding draws into 
question the identity of MFehi as a unique subtype of resident ATMs. The original 
discovery of MFehi defined them based on their intracellular iron content and then 
further associated an iron-handling gene profile with those cells. However, if MFelo can 
also take up iron in a high-iron context, then high-iron ATMs may simply represent the 
percent of ATMs that are accommodating the most iron when needed, rather than a 
unique phenotype or ATM subtype.  These ideas will be further parsed out in Future 
Directions (Chapter VII).  
 In both models of excess iron in lean mice, MFehi were able to take up excess 
iron, and adipocytes showed no uptake of iron. This was particularly unexpected in the 
iron-injection model, as this was an extreme model of iron excess. However, it served 
well as a proof-of-concept that MFehi ATMs could function as an iron sink. It also further 
supports the ability of MFehi to accommodate excess iron and compensate for the 
relative sensitivity of other metabolic cells, like adipocytes. Furthermore, the small 
percent of monocyte recruitment we observed demonstrates chronic adaptation of these 
resident macrophages to the iron-excess stimulus. For this reason, the iron-injection 
model was also applied in Chapter IV to assess the impact of obesity on MFehi iron 
uptake.  
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 The experiments outlined in Chapter IV intended to address how ATMs respond 
to excess iron in the obese setting. The studies were designed around previous findings 
that adipocytes have a 4-fold increase in iron content in obesity, while MFehi have 
decreased iron content. Orr et al. hypothesized that this demonstrated a “dysfunction” of 
MFehi in obesity. However, the data in this chapter did not directly address this 
hypothesis. While the experiments intended to test adipocyte response to excess iron in 
obesity, it ultimately demonstrated decreased iron content in control groups in obesity –
contradicting previous findings71. To reconcile these conflicting findings we designed 
studies to understand the timing of HFD weight gain in the context of AT and liver iron 
content with lipid storage. Unfortunately, the negative results of these studies did not 
help to clarify our initial findings. As with all conflicting results, the data outlined in this 
chapter offer an opportunity for further studies regarding adipocyte iron content in 
obesity, as discussed in Future Directions (Chapter VII).  
 Chapter V outlined two methods used to target M2-polarized ATMs. While both 
technologies were developed with the intention of targeting M2-like macrophages, their 
application to ATMs is promising. CD163lipos are mainly useful for cellular depletion. 
This means that their experimental and pharmaceutical utility is contingent on their 
ability to target specific tissues; depleting the same cell type, like M2-like macrophages, 
in many tissues could lead to unacceptable adverse effects. Therefore, it is important to 
note the specific uptake of CD163lipo/calcein in only AT of the peritoneum is extremely 
promising. Furthermore, selective depletion of CD163hi MFehi ATMs demonstrated even 
greater potential applications for CD163lipo/dox. However, when we applied 
CD163lipo/dox to our high-iron model we observed confounding results – iron uptake by 
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adipocytes even in empty liposome control groups. It is interesting to consider if 
CD163lipos are able to activate complement, and that this may impact adipocytes,173 
possibly influencing iron uptake. The potential utility of C163-targeting liposomes as a 
method for further research studies is outlined in Future Directions (Chapter VII). 
 In contrast to cytotoxic liposomes, MnNPs are made to target cellular function via 
siRNA against specific mRNA. So, tissue-specific uptake may be less critical than for 
cytotoxic liposomes. i.e. Altering only iron-handling by M2-like macrophages in different 
tissues may not have as dramatic adverse effects as abolishing those cells completely. 
However, for research and pharmaceutical applications, it is absolutely required that 
MnNPs deliver their cargo consistently, because siRNA is expensive and functionally 
limited by its protected status within the micelle. Based on the results of our preliminary 
studies, we determined that the MnNPs provided to us did not fulfill these criteria. For 
this reason, we chose not to move forward with in vivo studies with these MnNPs. 
However, should the technology evolve, they could very experimentally useful, as 
described in Future Directions (Chapter VII).  
 Generally, the studies in these chapters address how ATMs may respond to 
conditions of iron excess, possibly protecting adipocytes. By understanding the normal 
roles of macrophages in tissues, we lay the groundwork for future methods that may 
intervene to alter the physiology of AT – such as liposomes or nanoparticles.   
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Figure 5.7. Model representing a summary of dissertation scope and findings. Previous studies by 
our lab demonstrated that MFehi ATMs have increased intracellular iron content. In obesity, the iron 
content of MFehi is decreased but adipocyte iron increases. The findings described in Chapter III 
demonstrated the proof-of-concept that MFehi act as an iron-sink in models of excess iron. Chapter IV 
outlined studies showing that MFehi can still take up excess iron in obesity. In Chapter V we explored 
methods of interfering with MFehi uptake of iron. 
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CHAPTER VII  
 
FUTURE DIRECTIONS  
 
 The studies detailed in this dissertation provide insights into the function of ATMs 
in regards to iron-handling. However, these same results led to more questions, 
providing a rich resource for further research in the area of ATM-associated iron 
handling. In the following sections, these future directions have been structured as a 
specific set of questions, along with potential experimental plans. 
 
Do MFehi have an increased labile iron pool (LIP)? 
 The MFehi population was defined as the 80-90% of the paramagnetic fraction 
that stains positive for macrophage markers. Using this same definition, MFehi can be 
sorted by FACS, in order to assess their gene expression. To the surprise of Orr et al., 
MFehi did not have a gene profile that reflected iron-storage, but had higher expression 
of all iron-handling genes, relative to MFelo. This is especially surprising considering the 
IRP-associated regulation of iron-associated genes. In the classic understanding, when 
a cell has an increase in free intracellular iron (the LIP), it increases its expression of 
iron-storage proteins (like Ft) and iron-releasing proteins (like Fpn), while down-
regulating iron-uptake proteins (like TfR1). All of this regulation is mediated through 
IRPs and exists to avoid the threat of oxidative stress posed by a high LIP.  However, 
the gene-expression seen in MFehi seems to contradict this classic regulatory 
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mechanism because iron-uptake, -storage, and -export genes are all upregulated. This 
may be explained in two ways: 
 (1) MFehi have a very unique phenotype in regards to iron handling that does not 
follow the classic IRP-IRE response, differentiating them from other macrophages. In 
order to demonstrate this, the LIP of MFehi would need to be quantified relative to gene 
expression. LIP can be quantified directly using calcein-AM quenching assays174, 175. 
These studies would be supported by using IRP-IRE-binding bandshift assays to 
quantify the binding of IRP in these cells176, 177.  These studies would allow us to place 
MFehi in the broader context of known mechanism of iron-handling by macrophages. 
 
 (2) The iron-cycling gene profile describe herein may actually be a reflection of 
MFehi ATMs existing at temporally different responses to iron uptake. For example: Cell 
1 may have been exposed to high iron one day ago, so it has had time to respond 
through IRPs, increasing Fpn and Ft expression and decreasing TfR1. Cell 1 would 
have a lower LIP but high intracellular iron. In contrast, Cell 2 may be actively taking up 
iron from the local microenvironment, with a growing LIP that is giving it the same 
paramagnetic qualities as Cell 1. However, Cell 2 still has high Tfrc, and low Slc40a1 
and Ft expression. When both cells sort as paramagnetic in the AutoMACS and as 
macrophages via FACS, their pooled gene expression would appear to have 
upregulation in all genes, relative to MFelo. This hypothesis is supported by the 
response of MFehi to high-iron studies; in both models of iron excess, the baseline 
MFehi gene profiles is reflective an IRP-regulated response. Ultimately, considering that 
iron-handling proteins are regulated by IRPs that actively impact the stability of 
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mRNA178, the gene expression profiles described may not reflect the state of the cells. 
The studies by Orr et al., and those in this dissertation, used a gene expression readout 
because they were limited by low counts of MFehi.  There are multiple methodological 
options available to clarify this question. In both cases, it would be beneficial to compare 
ATMs from untreated and iron-treated mice in order to determine the impact of 
microenvironmental iron availability. One option is to use flow cytometry120 or plated 
fluorescent antibody-mediated cell imaging to quantify protein levels of all the iron-
handling proteins and see if they are expressed by the same cells. Another option is to 
use carefully optimized Western Blotting techniques for low protein levels, or 
proteomics179, in order to accurately determine the iron-handling state of the MFehi and 
MFelo on a protein level. 
 
Are MFehi a unique subpopulation? 
 In our studies investigating MFehi in iron-excess conditions, we noted an 
unexpected increase in the count of MFehi. For iron-injection studies, this increase could 
primarily be attributed to MFelo “switching” to MFehi. These findings may suggest that 
MFehi are not, in fact, a unique subpopulation of ATMs, but simply those ATMs in lean 
tissue that happen to take up iron where it is present in the microenvironment. This in 
no way mitigates the importance of iron-handling by M2-polarized ATMs. Future studies 
concerning MFehi could address this question in the following ways: 
 
 (1) The entire ATM population from a lean AT could be sorted and plated in vitro. 
They would then be exposed to either M2- or Mme-polarization stimulus as well as high-
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iron in order to determine how they alter their iron uptake or iron-handling. The cell-
specific response would be best quantified by cell fixation and fluorescent antibody-
mediated imaging. Furthermore, comparison of M2- and Mme-polarized to a control un-
polarized group would demonstrate how heterogeneous the ATMs were initially. This 
experimental setup effectively removes the micro-environmental differences in iron 
availability that may be underlying heterogeneity observed in vivo.  
 
 (2) The studies described could be taken a step further by performing a cross-
over experiment, where the polarization stimulus is switched in the context of high iron. 
This type of experiment would begin to address the impact that an obesity-associated 
inflammatory state may have on ATM iron handling. This is especially interesting 
because in Chapter IV we described that in the obese AT, MFehi still took up excess iron 
but their iron-cycling phenotype was blunted.  Lastly, BMDMs or macrophages from 
other sources – like red pulp macrophages – could be used in parallel experiments to 
demonstrate how ATMs respond to these stimuli relative to other macrophages.  
 
Are MFehi (or ATMs) also responsive to, or required, in low-iron conditions? 
 Some results from low iron diet studies suggest that MFehi are homeostatically 
responsive to iron; after 8 weeks of low iron, there are reduced counts of MFehi and 
lower MFehi iron concentrations (Fig. 3.2A - C). “Iron-cycling” is used as a descriptor of 
the MFehi gene profile. However, the studies included in Chapters III-V were more 
heavily weighted towards high iron, not low iron. Future studies could incorporate the 
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following experimental designs with iron-demand conditions to establish that MFehi 
partake in bidirectional homeostatic responses.  
 
 (1) Iron chelation can be applied in the same contexts as iron-excess, both in 
vitro and in vivo. In vitro studies would be similar to those previously described: whole 
ATM population would be plated, exposed to polarization stimulus, and then treated with 
a chelator, like deferoxamine. The advantage of in vivo studies is that they could directly 
complement iron-injection studies. However, in vitro studies circumvent the whole-body 
physiologic adaptation that may buffer efforts to chelate iron in the peritoneum (the liver 
may simply release iron or more iron may be absorbed from the GI tract, such that a 
true state of iron depletion would not be achieved in vivo).  
 
 (2) Physiologic relevance could be attained in vivo by investigating the role of 
ATMs during a natural state of AT iron demand – AT hyperplasia. All replicating cells 
require iron to produce iron-containing genes, especially for mitochondrial replication. In 
fact, iron chelation has been shown to inhibit replication and differentiation in adipocyte 
cell lines77. Therefore, the expanding tip of a fat pad likely represents an iron-
demanding microenvironment. Previous studies have shown that macrophages are 
intimately involved, even required, for AT development and expansion180. Iron provision 
could be one of the functions that they perform in this context. This idea could be 
approached by separating the tip of a fat pad undergoing hyperplasia – like in early 
stages of development or HFD – and comparing relative ratios of MFehi to MFelo to 
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other parts of the fat pad, either by flow or iron staining. The cells could also be 
analyzed for iron-handling proteins by flow cytometry.  
 
 (3) Once optimized, CD163lipos or MnNPs carrying anti-Fpn siRNA could be 
injected during early stages of AT hyperplasia. These studies would demonstrate 
whether ATMs, or specific iron-handling functions, are required for healthy hyperplasia. 
 
Is SpiC an important developmental gene for iron-handling ATMs? 
 Spic is a protein required for the development of iron-handling red pulp 
macrophages of the spleen. Its expression has also been found to be elevated in MFehi 
compared to MFelo (4.6G).  However, this difference was lost following iron-injections or 
HFD. This may indicate two things – either the elevation in SpiC in MFehi at baseline is 
subtle and insignificant, or it demonstrates that MFehi are in fact a unique subpopulation 
with unique developmental genes. These questions could be addressed in two mains 
ways: 
 
 (1) In vivo changes in SpiC are confounded by shifts of MFelo to paramagnetic 
fractions, as has been previously discussed. To avoid this confounding effect, SpiC 
could be quantified in unsorted ATMs sourced after multiple iron injections, or long-term 
iron diet.  A long exposure to iron is suggested for these studies in order to allow for 
detectable responses in developmental gene expression in ATMs. Alternatively, plated 
ATMs could be exposed to iron in vitro. This would demonstrate if only some, or all, 
ATMs alter SpiC levels in response to iron. 
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 (2) These questions could be further addressed with inducible SpiC knockout 
mice. In this case, it would be interesting to induce the knockout prior to iron injections 
or prior to the initiation of AT hyperplasia (like HFD, an iron-demand scenario), and 
compare the adipocyte response between knockout and control mice. ATMs from 
conditional knockout mice could also be used in vitro under conditions of high or low 
iron to investigate if knockout of SpiC impacts the availability of ATMs that regulate iron.  
 
 During the last months with the Hasty lab, I intend to delve into some of the 
studies described – particularly, the application of CD163lipos in vivo, and MFehi during 
adipogenesis. However, most of these Future Directions remain as potential studies of 
interest for students of the Hasty lab to explore. Not only will understanding ATM iron 
handling satisfy our curiosity on the role of immune cells in AT, but these studies may 
lead to therapeutic targets for situations of AT dysfunction down the line. 
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